

S.D.N.Y.—N.Y.C.
24-cv-6653
Swain, C.J.

United States Court of Appeals
FOR THE
SECOND CIRCUIT

At a stated term of the United States Court of Appeals for the Second Circuit, held at the Thurgood Marshall United States Courthouse, 40 Foley Square, in the City of New York, on the 17th day of April, two thousand twenty-five.

Present:

Raymond J. Lohier, Jr.,
Joseph F. Bianco,
Eunice C. Lee,
Circuit Judges.

Marcus Brent Fields,

Plaintiff-Appellant,

v.



24-2735

Pfizer Inc., et al.,

Defendants-Appellees.

Appellant, pro se, moves for leave to proceed in forma pauperis (“IFP”), a protective order, appointment of counsel, and a jury trial. Upon due consideration, it is hereby ORDERED that the motion for IFP status is DENIED and the appeal is DISMISSED because it “lacks an arguable basis either in law or in fact.” *Neitzke v. Williams*, 490 U.S. 319, 325 (1989); *see also* 28 U.S.C. § 1915(e). It is further ordered that the remaining motions are DENIED as moot.

FOR THE COURT:
Catherine O’Hagan Wolfe, Clerk of Court

**UNITED STATES COURT OF APPEALS
FOR THE
SECOND CIRCUIT**

At a stated term of the United States Court of Appeals for the Second Circuit, held at the Thurgood Marshall United States Courthouse, 40 Foley Square, in the City of New York, on the 10th day of July, two thousand twenty-five.

Marcus Brent Fields,

Plaintiff - Appellant,

v.

Pfizer Inc., et al.

Defendants - Appellees.

ORDER



Docket No: 24-2735

Appellant, Marcus Brent Fields, filed a motion for panel reconsideration, or, in the alternative, for reconsideration *en banc*. The panel that determined the appeal has considered the request for reconsideration, and the active members of the Court have considered the request for reconsideration *en banc*.

IT IS HEREBY ORDERED that the motion is denied.

FOR THE COURT:

Catherine O'Hagan Wolfe, Clerk

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK

MARCUS BRENT FIELDS,

Plaintiff,

-against-

PFIZER CEO ALBERT BOURIA, ET AL.,

Defendants.

24-CV-6653 (LTS)

ORDER OF DISMISSAL UNDER
28 U.S.C. § 1915(g)

LAURA TAYLOR SWAIN, Chief United States District Judge:

Plaintiff, who is currently incarcerated at Kern Valley State Prison in Delano, California, brings this action *pro se*. Plaintiff did not pay the filing fees to bring this action, and the Court understands that Plaintiff seeks leave to proceed without prepayment of fees, that is, *in forma pauperis* (“IFP”). Plaintiff is barred, however, from filing any new action IFP while he is a prisoner. *See Fields v. Macomber*, No. 23-CV-01575, 2023 WL 7926803, at *2 (S.D. Cal. Nov. 16, 2023).¹

That order relied on the “three-strikes” provision of the Prison Litigation Reform Act (PLRA), 28 U.S.C. § 1915(g), which provides that:

In no event shall a prisoner bring a civil action [IFP] if the prisoner has, on 3 or more prior occasions, while incarcerated or detained in any facility, brought an action or appeal in a court of the United States that was dismissed on the grounds that it is frivolous, malicious, or fails to state a claim upon which relief may be granted, unless the prisoner is under imminent danger of serious physical injury.

¹ *See Fields v. Newsom*, No. 22-CV-00044 (S.D. Cal. May 16, 2022) (dismissing amended complaint for failure to state a claim and as frivolous); *Fields v. Newsom*, No. 22-55519 (dismissing appeal as frivolous) (9th Cir. Nov. 17, 2022); *Fields v. Bouria*, No. 22-CV-01656 (S.D. Cal. Nov. 18, 2022) (dismissing complaint for failure to state a claim and as frivolous), No. 22-56171 (dismissing appeal as frivolous) (9th Cir. May 18, 2023).

Although Plaintiff has filed this new action seeking IFP status, his complaint does not show that he is in imminent danger of serious physical injury.¹ Instead, Plaintiff alleges that in March 2021, he received a “harmful Pfizer Covid 19 vaccine shot.” (ECF 1 ¶ V.) Plaintiff is therefore barred from filing this action IFP.

CONCLUSION

The Court denies Plaintiff’s request to proceed IFP, and the complaint is dismissed without prejudice under the PLRA’s “three-strikes” rule. *See* 28 U.S.C. § 1915(g).² Plaintiff remains barred from filing any future action IFP while he is in custody, unless he is under imminent threat of serious physical injury.³ *Id.*

The Court certifies, pursuant to 28 U.S.C. § 1915(a)(3), that any appeal from this order would not be taken in good faith, and therefore IFP status is denied for the purpose of an appeal. *See Coppedge v. United States*, 369 U.S. 438, 444-45 (1962).

¹ An imminent danger is one “existing at the time the complaint is filed.” *Malik v. McGinnis*, 293 F.3d 559, 563 (2d Cir. 2002). A danger “that has dissipated by the time a complaint is filed” is not sufficient. *Pettus v. Morgenthau*, 554 F.3d 293, 296 (2d Cir. 2009).

² Plaintiff may commence a new action by paying the filing fee. If Plaintiff does so, that complaint will be reviewed under 28 U.S.C. § 1915A, which requires the Court to dismiss *any* civil rights complaint from a prisoner if it “(1) is frivolous, malicious, or fails to state a claim upon which relief may be granted; or (2) seeks monetary relief from a defendant who is immune from such relief.” 28 U.S.C. § 1915A(b).

³ The Court may bar any vexatious litigant (including a nonprisoner) from filing future actions (even if the filing fee is paid) without first obtaining leave from the Court. *See In re Martin-Trigona*, 9 F.3d 226, 227-30 (2d Cir. 1993) (discussing sanctions courts may impose on vexatious litigants, including “leave of court” requirement).

The Clerk of Court is directed to enter judgment.

SO ORDERED.

Dated: September 11, 2024
New York, New York

/s/ Laura Taylor Swain

LAURA TAYLOR SWAIN
Chief United States District Judge

PUBLIC DOCKET FOR
United States Court of Appeals for the Second Circuit

Court of Appeals Docket #: 24-2735

Docketed: 10/17/2024

Case Name: Fields v. Pfizer

Status: Determined

Nature of Suit: 3550 PRISONER PET-Civil Rights

Appeal From: SDNY (NEW YORK CITY)

Fee Status: IFP Pending in USCA

Case Type Information

1. Prisoner
2. State
3. Civil Rights

Originating Court Information

District: SDNY (NEW YORK CITY): 1:24-cv-6653

Trial Judge: Laura Taylor Swain, Chief District Judge

Date Filed: 08/28/2024

Date Order/Judgment	Date Order/Judgment EOD	Date NOA Filed	Date Rec'd COA
09/11/2024	09/16/2024	10/09/2024	10/11/2024

Associated Cases

Party and Attorney Listing

MARCUS BRENT FIELDS
V46240,
Plaintiff - Appellant

Marcus Brent Fields
[Pro Se]
Richard J. Donovan Correctional Facility
480 Alta Road
San Diego, CA 92179

PFIZER INC.
Defendant - Appellee

Pfizer Inc.
[Pro Se]
66 Hudson Boulevard East
New York, NY 10007

ALBERT BOURLA, CEO
Defendant - Appellee

Albert Bourla
[Pro Se]
235 East 42nd Street
New York, NY 10017

DREW WEISSMAN, Covid-19 MRNA Inventor
Defendant - Appellee

KATALIN KARIKO, Bio-N-Tech, Bio-Chemist
Defendant - Appellee

JOHN AND JANE DOES, Scientist-Chemist-
Physicist
Defendant - Appellee

UGAR SAHIN, Bio-N-Tech C.E.O.
Defendant - Appellee

Marcus Brent Fields,

Plaintiff - Appellant,

v.

Pfizer Inc., Albert Bourla, CEO, Drew Weissman, Covid-19 MRNA Inventor, Katalin Kariko, Bio-N-Tech,
Bio-Chemist, John and Jane Does, Scientist-Chemist-Physicist, Ugar Sahin, Bio-N-Tech C.E.O.,

Defendants - Appellees.

Docket

LEGEND:
(R) - Restricted Document
(L) - Locked Document

Date Filed	Entry #	Public Docket Text
10/11/2024	1	NOTICE OF PRISONER APPEAL, with district court docket, on behalf of Appellant Marcus Brent Fields, FILED. [Entered: 10/17/2024 12:25 PM]
10/11/2024	2	DISTRICT COURT ORDER, dated 09/11/2024, RECEIVED. [Entered: 10/17/2024 12:29 PM]
10/11/2024	3	ELECTRONIC INDEX, in lieu of record, FILED. [Entered: 10/17/2024 12:36 PM]
10/11/2024	9	(L) MOTION, demand for jury trial, on behalf of Appellant Marcus Brent Fields, FILED. [Entered: 10/17/2024 01:40 PM]
10/17/2024	4	PRISONER APPEAL, on behalf of Appellant Marcus Brent Fields, received by 10/11/2024, OPENED. [Entered: 10/17/2024 12:43 PM]

Date Filed	Entry #	Public Docket Text
10/17/2024	5	INSTRUCTIONAL FORMS, to Pro Se Appellant Marcus Brent Fields, SENT. [Entered: 10/17/2024 12:53 PM]
10/17/2024	6	INSTRUCTIONAL FORMS, to Pro Se Appellee Albert Bourla SENT. [Entered: 10/17/2024 01:06 PM]
10/17/2024	7	NOTICE, to Pfizer Inc., regarding a corporation proceeding Pro Se, and requesting a response 30 days from the date of this letter, SENT. [Entered: 10/17/2024 01:16 PM]
10/17/2024	8	AUTHORIZATION FORM, REQUESTED. [Entered: 10/17/2024 01:22 PM] [Edited: 10/18/2024 08:48 AM]
10/17/2024	10	DEFECTIVE DOCUMENT, motion, demand for jury trial, at docket entry 9, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 10/17/2024 01:53 PM]
10/23/2024	11	NEW PARTY, Appellee Ugar Sahin, ADDED. [Entered: 10/23/2024 03:50 PM]
10/23/2024	12	CAPTION, added Appellee Ugar Sahin, AMENDED. [Entered: 10/23/2024 04:04 PM]
11/01/2024	13	NOTICE, to Appellee, for failure to file an appearance, SENT. [Entered: 11/01/2024 10:34 AM]
11/04/2024	14	ORDER, dated 11/04/2024, stating this appeal may be subject to dismissal by 11/25/2024, unless appellant Marcus Brent Fields, submits fee or moves for in forma pauperis, copy to pro se appellant, FILED. [Entered: 11/04/2024 04:20 PM]
11/04/2024	15	ORDER, dated 11/04/2024, stating this appeal may be subject to dismissal by 11/25/2024, unless appellant Marcus Brent Fields, submits form D-P, copy to pro se appellant, FILED. [Entered: 11/04/2024 04:29 PM]
11/04/2024	16	ORDER, dated 11/04/2024, stating this appeal may be subject to dismissal by 11/25/2024, unless appellant Marcus Brent Fields, submits an Acknowledgment and Notice of Appearance, copy to pro se appellant, FILED. [Entered: 11/04/2024 04:36 PM]
11/13/2024	17	(L) ACKNOWLEDGMENT AND NOTICE OF APPEARANCE, on behalf of Appellant Marcus Brent Fields, FILED. Service date 10/30/2024 by United States Mail. [Entered: 11/16/2024 09:55 PM]
11/13/2024	18	PRISON LITIGATION REFORM ACT AUTHORIZATION FORM, FILED. Service date 11/13/2024 by No Service. [Entered: 11/16/2024 09:58 PM]
11/13/2024	19	LR 31.2 SCHEDULING NOTIFICATION, on behalf of Appellant Marcus Brent Fields, informing Court of proposed due date 11/28/2024, RECEIVED. Service date 10/30/2024 by United States Mail. [Entered: 11/16/2024 10:00 PM]
11/13/2024	20	(L) MOTION, for extension of time, permission to mail on behalf of Appellant Marcus Brent Fields, FILED. Service date 10/30/2024 by United States Mail. [Entered: 11/16/2024 10:06 PM]
11/13/2024	21	(L) MOTION, to proceed in forma pauperis, on behalf of Appellant Marcus Brent Fields, FILED. Service date 10/30/2024 by United States Mail. [Entered: 11/16/2024 10:08 PM]

Date Filed	Entry #	Public Docket Text
11/13/2024	22	(L) FORM D-P, on behalf of Appellant Marcus Brent Fields, FILED. Service date 10/30/2024 by United States Mail. [Entered: 11/16/2024 10:10 PM]
11/13/2024	23	UNDELIVERABLE MAIL, for Appellee Albert Bourla to USCA from USPS, received on 11/13/2024, RECEIVED. [Entered: 11/16/2024 10:14 PM]
11/13/2024	25	PAPERS, Additional PLRA Form, RECEIVED. [Entered: 11/16/2024 10:42 PM]
11/14/2024	24	(L) MOTION, for jury trial, on behalf of Appellant Marcus Brent Fields, FILED. Service date 11/14/2024 by No Service. [Entered: 11/16/2024 10:40 PM]
11/18/2024	26	DEFECTIVE DOCUMENT, motion for jury trial, at docket entry 24, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 11/18/2024 01:42 PM]
11/18/2024	30	UNDELIVERABLE MAIL, for Appellee Albert Bourla to USCA from USPS, received on 11/18/2024, RECEIVED. [Entered: 11/25/2024 07:26 PM]
11/19/2024	27	DEFECTIVE DOCUMENT, the motion for extension of time, at docket entry 20, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 11/19/2024 11:27 AM]
11/19/2024	28	DEFECTIVE DOCUMENT, motion to proceed in forma pauperis, at docket entry 21, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 11/19/2024 11:34 AM]
11/22/2024	29	CERTIFIED PRISONER AUTHORIZATION FORM, dated 11/22/2024, to Richard J. Donovan Correctional Facility, In care of Warden, ISSUED. [Entered: 11/22/2024 12:26 PM]
11/27/2024	31	UNDELIVERABLE MAIL, for to USCA from USPS for Appellee Albert Bourla, received on 11/25/2024, RECEIVED. [Entered: 11/27/2024 11:39 AM]
12/02/2024	32	UNDELIVERABLE MAIL, for Appellee Albert Bourla to USCA from USPS, received on 12/02/2024, RECEIVED. [Entered: 12/03/2024 08:06 PM]
12/05/2024	33	MOTION, for assignment of pro bono counsel, on behalf of Appellant Marcus Brent Fields, FILED. Service date 11/25/2024 by United States Mail. [Entered: 12/06/2024 08:35 AM]
12/05/2024	34	MOTION, to proceed in forma pauperis, for jury trial, for extension of time on behalf of Appellant Marcus Brent Fields, FILED. Service date 11/24/2024 by United States Mail. [Entered: 12/06/2024 08:46 AM]
12/05/2024	35	ACKNOWLEDGMENT AND NOTICE OF APPEARANCE, on behalf of Appellant Marcus Brent Fields, FILED. Service date 11/24/2024 by United States Mail. [Entered: 12/06/2024 08:48 AM]
12/05/2024	36	FORM D-P, on behalf of Appellant Marcus Brent Fields, FILED. Service date 11/24/2024 by United States Mail. [Entered: 12/06/2024 08:50 AM]
12/10/2024	37	CURED DEFECTIVE DOCUMENT, motion, to proceed in forma pauperis, for jury trial, extension of time, at entry 34, on behalf of Appellant Marcus Brent Fields, FILED. [Entered: 12/10/2024 09:42 AM] [Edited: 12/10/2024 09:44 AM]

Date Filed	Entry #	Public Docket Text
12/13/2024	38	UNDELIVERABLE MAIL, for Appellee Pfizer Inc. to USCA from USPS, received on 12/13/2024, RECEIVED. [Entered: 12/16/2024 12:01 PM]
01/03/2025	39	TRUST ACCOUNT STATEMENT, on behalf of Appellant Marcus Brent Fields, FILED. Service date 12/09/2024 by U.S. Mail. [Entered: 01/06/2025 10:38 AM]
03/11/2025	40	NOTICE, Case Status, SENT. [Entered: 03/11/2025 05:00 PM]
04/08/2025	41	SUPPLEMENTARY PAPERS TO MOTION TO PROCEED IN FORMA PAUPERIS, FOR JURY TRIAL, FOR EXTENSION OF TIME, on behalf of Appellant Marcus Brent Fields, FILED. Service date 12/09/2024 by United States Mail. [Entered: 04/10/2025 06:52 PM]
04/15/2025	42	DEFECTIVE DOCUMENT, Form D-P, at docket entry 22, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 04/15/2025 12:35 PM]
04/15/2025	43	CURED DEFECTIVE DOCUMENT, Form D-P, at entry 36, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 04/15/2025 12:37 PM]
04/15/2025	44	DEFECTIVE DOCUMENT, Acknowledgment and Notice of Appearance Form, at docket entry 17, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 04/15/2025 12:43 PM]
04/15/2025	45	CURED DEFECTIVE DOCUMENT, Acknowledgment and Notice of Appearance Form, at entry 35, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 04/15/2025 12:44 PM]
04/17/2025	46	NEW CASE MANAGER, Khadijah Young, ASSIGNED. [Entered: 04/17/2025 01:51 PM]
04/17/2025	47	MOTION ORDER, denying motion to proceed in forma pauperis, denying as moot motions for a protective order, appointment of counsel, and a jury trial, on behalf of Appellant Marcus Brent Fields; and the appeal is dismissed, by RJL, JFB, ECL, copy to pro se appellant, FILED. [Entered: 04/17/2025 02:03 PM]
05/09/2025	48	(L) MOTION, for rehearing en banc, decrease in monetary damages, on behalf of Appellant Marcus Brent Fields, FILED. Service date 04/24/2025 by United States Mail. [Entered: 05/12/2025 03:58 PM] [Edited: 05/12/2025 04:19 PM]
05/12/2025	49	DEFECTIVE DOCUMENT, Motion for Rehearing en banc, decrease in monetary damages, at docket entry 48, on behalf of Appellant Marcus Brent Fields, FILED. [Entered: 05/12/2025 04:17 PM]
06/03/2025	50	MOTION, for reconsideration en banc, on behalf of Appellant Marcus Brent Fields, FILED. Service date 05/23/2025 by United States Mail. [Entered: 06/03/2025 02:34 PM]
06/03/2025	51	MOTION, for permission to add exhibits to motion for reconsideration en banc, on behalf of Appellant Marcus Brent Fields, FILED. Service date 05/23/2025 by United States Mail. [Entered: 06/03/2025 02:38 PM]
06/03/2025	52	CURED DEFECTIVE DOCUMENT, Motion, at entry 50, on behalf of Appellant Marcus Brent Fields, FILED. [Entered: 06/03/2025 02:40 PM]

Date Filed	Entry #	Public Docket Text
06/03/2025	53	PAPERS, motion for monetary reduction and error in USDC-SDNY, RECEIVED. [Entered: 06/03/2025 02:48 PM]
06/05/2025	54	MOTION ORDER, granting motion for permission to attach exhibits at docket entry 51, on behalf of Appellant Marcus Brent Fields, by ECL, copy to pro se Appellant and Appellee, FILED. [Entered: 06/05/2025 01:02 PM]
06/16/2025	55	UNDELIVERABLE MAIL, for Appellee Albert Bourla to USCA from USPS, received on 06/16/2025, RECEIVED. [Entered: 06/17/2025 01:04 PM]
06/24/2025	56	MOTION, to add exhibits and for default judgment, on behalf of Appellant Marcus Brent Fields, FILED. Service date 06/12/2025 by United States Mail. [Entered: 06/25/2025 12:33 PM]

Docket as of 6/25/2025 3:54 PM

MANDATE

S.D.N.Y.—N.Y.C.
24-cv-6653
Swain, C.J.

United States Court of Appeals
FOR THE
SECOND CIRCUIT

At a stated term of the United States Court of Appeals for the Second Circuit, held at the Thurgood Marshall United States Courthouse, 40 Foley Square, in the City of New York, on the 17th day of April, two thousand twenty-five.

Present:

Raymond J. Lohier, Jr.,
Joseph F. Bianco,
Eunice C. Lee,
Circuit Judges.

Marcus Brent Fields,

Plaintiff-Appellant,

v.

24-2735

Pfizer Inc., et al.,

Defendants-Appellees.

Appellant, pro se, moves for leave to proceed in forma pauperis ("IFP"), a protective order, appointment of counsel, and a jury trial. Upon due consideration, it is hereby ORDERED that the motion for IFP status is DENIED and the appeal is DISMISSED because it "lacks an arguable basis either in law or in fact." *Neitzke v. Williams*, 490 U.S. 319, 325 (1989); *see also* 28 U.S.C. § 1915(e). It is further ordered that the remaining motions are DENIED as moot.

FOR THE COURT:

Catherine O'Hagan Wolfe, Clerk of Court

A True Copy

Catherine O'Hagan Wolfe, Clerk

United States Court of Appeals, Second Circuit

Catherine O'Hagan Wolfe



MANDATE ISSUED ON 07/17/2025

Medication List

Patient : FIELDS, MARCUS BRENT
Address :
Phone :

Med Rec # : V46240
DOB : 03/18/76
Sex : Male
Physician : Sedighi, Fred P&S

All Active Medications

Medications

budesonide-formoterol (Symbicort 160 mcg-4.5 mcg/inh inhalation aerosol)

2, puff, Inhale, Aerosol, BID-KOP, Administration Type KOP, Automatic Refill, Medication Indication severe persistent asthma, Dulera, Symbicort 80 mcg, failed N/A, Order Duration: 180 day, Stop Date: 10/31/25 13:59:00 PDT, First Dose: 05/04/25 14:00:0...

hydroCHLORothiazide

25 mg, Oral, Tab, Daily-KOP, Administration Type KOP, Automatic Refill, Order Duration: 180 day, First Dose: 05/04/25 14:00:00 PDT, Stop Date: 10/31/25 13:59:00 PDT

busPIRone (BuSpar)

15 mg, Oral, Tab, BIDAM+PM, Administration Type DOT, Automatic Refill, Order Duration: 180 day, First Dose: 04/04/25 19:00:00 PDT, Stop Date: 10/01/25 18:59:00 PDT

divalproex sodium (Depakote ER)

1,000 mg, Oral, Tab-ER, qPM, Administration Type NA, Automatic Refill, Order Duration: 180 day, First Dose: 04/04/25 19:00:00 PDT, Stop Date: 10/01/25 18:59:00 PDT

diphenhydRAMINE (Benadryl)

25 mg, Oral, Cap, BID12+PM, PRN anxiety, Administration Type DOT, Automatic Refill, Medication Indication anxiety, vistaril, no benefit MAPIP, Order Duration: 180 day, Stop Date: 10/01/25 12:54:00 PDT, First Dose: 04/04/25 12:55:00 PDT

amLODIPine

10 mg, Oral, Tab, Daily-KOP, Administration Type KOP, Automatic Refill, Order Duration: 180 day, First Dose: 03/16/25 14:00:00 PDT, Stop Date: 09/12/25 13:59:00 PDT

cholecalciferol (Vitamin D3)

1,000 unit, Oral, Tab, Daily-KOP, Administration Type KOP, Automatic Refill, Order Duration: 180 day, First Dose: 03/15/25 14:00:00 PDT, Stop Date: 09/11/25 13:59:00 PDT

docusate (Colace)

100 mg, Oral, Cap, BID-KOP, PRN constipation, Administration Type KOP, Order Duration: 180 day, First Dose: 01/15/25 14:00:00 PST, Stop Date: 07/14/25 13:59:00 PDT, 01/15/25 14:00:00 PST

colloidal oatmeal topical (Eucerin Eczema Relief Creme)

1 app, Topical, Cream, Daily-KOP, PRN eczema, Administration Type KOP, Order Duration: 120 day, First Dose: 01/08/25 14:00:00 PST, Stop Date: 05/08/25 13:59:00 PDT, 01/08/25 14:00:00 PST

ibuprofen

400 mg, Oral, Tab, BID-KOP, PRN pain, Administration Type KOP, Order Duration: 180 day, First Dose: 01/03/25 14:00:00 PST, Stop Date: 07/02/25 13:59:00 PDT, 01/03/25 14:00:00 PST

melatonin (Melatonin)

3 mg, Oral, Tab, qPM-KOP, PRN insomnia, Administration Type KOP, Medication Indication SLEEP, NONE, NONE, Order Duration: 180 NONE day, Stop Date: 06/21/25 13:59:00 PDT, First Dose: 12/23/24 14:00:00 PST, 12/23/24 14:00:00 PST

cetirizine

10 mg, Oral, Tab, Daily-KOP, PRN allergies, Administration Type KOP, Order Duration: 360 day, First Dose: 12/12/24 14:00:00 PST, Stop Date: 12/07/25 13:59:00 PST, 12/12/24 14:00:00 PST

rosuvastatin

5 mg, Oral, Tab, Daily-KOP, Administration Type KOP, Automatic Refill, Order Duration: 180 day, First Dose: 12/10/24 14:00:00 PST, Stop Date: 06/08/25 13:59:00 PDT, 12/10/24 14:00:00 PST

triamcinolone nasal (triamcinolone 55 mcg/inh nasal spray)

110 mcg = 2 spray, Each-nostril, Spray-Nasal, Daily-KOP, Administration Type KOP, Order Duration: 180 day, First Dose: 12/10/24 14:00:00 PST, Stop Date: 06/08/25 13:59:00 PDT, 12/10/24 14:00:00 PST

Medication List

Patient : FIELDS, MARCUS BRENT

Med Rec # : V46240

Address :

DOB : 03/18/76

Sex : Male

Phone :

Physician : Sedighi, Fred P&S

All Active Medications continued...

Medications continued...

levalbuterol (levalbuterol CFC free 45 mcg/inh inhalation aerosol)

90 mcg = 2 puff, Oral, Aerosol, q6hr-KOP, PRN shortness of breath or wheezing, Administration Type KOP, Medication Indication FOR ASTHMA, Order Duration: 360 day, First Dose: 12/01/24 14:00:00 PST, Stop Date: 11/26/25 13:59:00 PST, 12/01/24 14:00:00 PST...

budesonide-formoterol (Symbicort 160 mcg-4.5 mcg/inh inhalation aerosol)

2, puff, Inhale, Aerosol, BID-KOP, Administration Type KOP, Automatic Refill, Medication Indication severe persistent asthma, Dulera, Symbicort 80 mcg, failed, Order Duration: 180 N/A day, Stop Date: 05/04/25 13:59:00 PDT, First Dose: 11/05/24 14:00:00...

hydroCHLORothiazide

25 mg, Oral, Tab, Daily-KOP, Administration Type KOP, Automatic Refill, Order Duration: 180 day, First Dose: 11/05/24 14:00:00 PST, Stop Date: 05/04/25 13:59:00 PDT, 11/05/24 14:00:00 PST

VAERS Covid-19 vaccine - Adverse Event Report

6195,934 Reports through March-18-2021 - for Further information about scientific analysis of the covid-19 vaccine batch numbers

Metrics

They C.O.C.R- should have pre-screened + monitor every person in prison biological process.

- Reporting systems (VAERS) have detected a pattern showing that certain batches of the pfizer, moderna & J&J vaccine even by a 1000s of times. These specific batches are linked to the most deaths and illnesses and the pattern of these suggest that these companies are deliberately testing the strength of their surum. below listed are just some of the deadly Lot numbers ~~linked to the batches~~ and the deaths reported linked to the batches in the C.D.C - data. = See Attached page-2

Detailed, timely data on hospitalizations by age and race would help health officials identify and help the populations highest risk. Information on hospitalizations and death by age and vaccination status whether healthy or high-risk adults need vaccine booster shot.

Conventional vaccine manufacturing uses eggs to the risk gene transfer technology. Sources and References: The Defender march 21-2022 undumbare .net march 20, 2022 = Daily caller march 18-2022 .PJ media march-18-2022 = Health feedback fact check • Health data .gov. Jan-6-2022 The Atlantic Jan-18-2022, CBS DUSTON march-10-2022 = clinical infectious Diseases : september 28-2020 = Cjaal 1471 : white house Jan 14-2022 = 13 news Now march 3-2022 = 13 news .now Feb-11-2022 The New York times Feb-4-2022 = Impact Research Feb 24-2021

Lot #

Deaths

38

EN6201	117
EN5318	99
EN6200	97
EN6198	89
EL3248	86
EL9261	84
EM9810	82
EN6202	75
EL9269	75
EL3302	69
EL3249	67
EL8982	67
EN6208	59
EL9267	58
EL9264	57
EL0140	54
EN6199	54
EL1686	51
EL9265	50
EL1283	48
ER2613	48
ng infected number → EN6204	47
EN6205	45
EK9231	43
EL3246	43
EN6207	41
ER8732	40
EL1284	39
EL0142	38
EL1685	38
ER8737	37
EN9581	36
EN6206	35
EP7533	35
EL9262	34
EL9266	33
EL3247	32

Exhibit 3-4
See confirmed

RJD - RJ Donovan Correctional Facility

Patient: **FIELDS, MARCUS BRENT**

DOB/Age/Sex: 3/18/1976 / 49 years / Male

CDCR: V46240

Mental Health Documentation

New Issues/Complaints

Presenting Problem MH

11/07/24 10:54:00

During today's assessment Pt expressed wanting to sad and angry, trying to overcome everything and trying to pursue my freedom.

Being incarcerated caused a lot of my sadness and anger. Pt also expressed having a hard time articulating with others.

Pt has expressed rumination in regards to his court cases, lawsuits and his case directly. Pt appears to have some paranoia surrounding how others view him in which is a reason why he would like help with his communication skills.

Signed By: Corona, Joanna LCSW

Current Status of Illness

RP is diagnosed with ASPD, anxiety, other substance use disorder - severe, and schizoaffective disorder - depressive type. RP continues to present as irritable due to delusional beliefs about MHMD and medication related requests. RP reported more anxiety today even requesting to be placed on an anti-anxiety medication.

Collateral

Per MAR summary, RP is compliant with psychotropic medications.

Mental Status

Appearance: dressed in appropriate CDCR attire, non-malodorous, adequately groomed, wearing a white mesh head covering

Attitude: alert and oriented x4

Activity: no psychomotor agitation present

Mood: "not good"

Affect: irritable, congruent with reported mood

Speech: appropriate tone, rhythm, volume

Language: in English; understood

Eye contact: intact

Attention and Concentration: intact

Thought Process: circumstantial, future oriented

Thought Content: did not appear to be RTIS; some delusional ideation present; did not endorse VAH

Insight: poor

Judgment: fair

SI: denied

HI: denied

Mental Health Assessments

RP presented as stable as indicated by no mental health decompensation endorsed or observed. No observation of significant or acute stressors leading to crisis, defined as being unable to care of his basic needs (i.e. ADLs, feeding) or safety (danger to self, others) and no indication of grave disability. Therefore, RP was not currently deemed to be GD, DTO, or DTS. No LOC changes are expected at this time.

a routine session confidentially in office with 6ft of space for the safety of staff and RP. RP was assessed for urgent or emergent needs to be addressed. At this time RP did not present in acute psychiatric distress, and was not deemed a current risk of harm to self or others, nor gravely disabled.

RP reported he is "not good. I feel alone." PC probed into this further, with RP identifying "I keep my head down and am working on my moves. Putting in paperwork and holding people accountable." RP described having some anxiety and a desire to get on anti-anxiety medication. RP stated "he [MHMD] seems to be doing his own thing. I don't want to be put on forced medication but something to address my anxiety."

Problem List/Past Medical History

Ongoing

Obesity (Confirmed)
Hypertension (Confirmed)
Sickle cell trait (Confirmed)
Anxiety (Confirmed)
Hair loss (Confirmed)
Schizoaffective disorder, Depressive type (Confirmed)
Antisocial personality disorder (Confirmed)
Other (or unknown) substance use disorder, Severe, In sustained remission (Confirmed)
Gynecomastia (Confirmed)
Health care maintenance (Confirmed)
History of right bundle branch block (RBBB) (Confirmed)
Fatty liver (Confirmed)
Persistent asthma (Confirmed)
10 year risk of MI or stroke 7.5% or greater (Confirmed)
Allergic rhinitis (Confirmed)
Paranoia (Confirmed)
POLST (Physician Orders for Life-Sustaining Treatment) (Confirmed)
Suspected sleep apnea (Confirmed)

Historical

Diabetes mellitus without complication
Benign essential hypertension
Thyroid disorder
Non-cardiac chest pain
Low back pain
Headache

Report Request ID: 97028642

Print Date/Time: 4/30/2025 10:44 PDT

WARNING: This report contains confidential, proprietary, and/or legally privileged information intended for the recipient only.

RJD - RJ Donovan Correctional Facility

Patient: **FIELDS, MARCUS BRENT**
DOB/Age/Sex: 3/18/1976 / 49 years / Male

CDCR: V46240

Mental Health Documentation

Estimated Length of Stay

RP will remain in EOP LOC at this time. Current treatment goals are centered on psychosis management, mood management, and increasing insight. Treatment team will continuously reevaluate RP's appropriateness for EOP LOC over next routine 90 day period.

Assessment/Progress Towards Discharge

Dry skin
Obesity
Snoring

Plan/Disposition

PC used open-ended questions, active listening, and validation to assist in developing therapeutic rapport and assessing the patient's mental status, current functioning, and goals for treatment.

RP will be maintained at EOP LOC and seen at least once weekly via individual session or PC check-in group. PC and RP reviewed safety planning and coping skills. PC spoke with RP about how to ask for help if needed-- if there is an increase in SI or HI. PC encouraged RP to submit a 7362 should an emergency occur before next scheduled 1:1 contact. A referral to a higher LOC will be considered if RP experiences psychiatric decompensation or acute crisis, defined as being unable to care for his basic needs (i.e., ADL's, feeding) or safety issues (i.e., danger to self or others). PC encouraged RP to continue sharing thoughts and feelings with PC and provided empathy and validation. PC also encouraged RP to continue his self-identified coping skills which include completing legal paperwork and writing.

Constipation
Rash
Tinea capitis
Diabetes mellitus without complication
Diet-controlled type 2 diabetes mellitus

IPOC Goals

Current IPOCs

Goals(Activated):

Depressed Mood IPOC(Initiated) 02/06/2025 13:49

Indicators & Orders

Depressed Mood IPOC(Initiated) 02/06/2025 13:49

Outcomes & Interventions

Outcomes(Initiated):

Delusions IPOC(Initiated) 02/06/2025 13:36

Indicators & Orders

Delusions IPOC(Initiated) 02/06/2025 13:36

Outcomes & Interventions

Outcomes(Initiated):

Scales and Assessments Interpretations
(for assessments without
interpretations, please manually enter
one here)

No results documented

Suicide Risk Overview

No Data Found.

Encounter Info: Patient Name: MARCUS FIELDS, DOB: 03/18/1976, CDCR: V46240, FIN: 10000003511984938V46240, Facility: RJD, Encounter Type: Institutional Encounter

Document Type:	MHPC Progress Note
Document Subject:	MH PC Note
Service Date/Time:	2/27/2025 09:38 PST
Result Status:	Auth (Verified)
Perform Information:	Lewis, Madison Psychologist (2/27/2025 09:41 PST)
Sign Information:	Lewis, Madison Psychologist (2/27/2025 10:18 PST)
Authentication Information:	[Lewis, Madison Psychologist; Lewis, Madison Psychologist (2/27/2025 10:18 PST)]

Inmate's Program and Level of Care

Facility C, EOP.

Subjective/History of Present Illness

RP was seen for a biweekly EOP contact and routine consult by this writer. RP was seen for

Report Request ID: 97028642

Print Date/Time: 4/30/2025 10:44 PDT

WARNING: This report contains confidential, proprietary, and/or legally privileged information intended for the recipient only.


Right Bundle Branch Block



my.clevelandclinic.org/health/diseases/21692-right-bundle-branch-block

August 24, 2021

Overview



Heartbeat signal blocked in right bundle branch

What is right bundle branch block?

Right bundle branch block is an obstacle in your right bundle branch that makes your heartbeat signal late and out of sync with the left bundle branch, creating an irregular heartbeat.

Electrical signals in your heart act like a pacemaker that controls your heartbeats. This signal starts in the sinoatrial (SA) node, which tells your left and right atria (upper heart chambers) to contract. Next, the signal goes to your atrioventricular (AV) node and bundle branches, which make your left and right ventricles tighten.

Normally, the signal goes down both bundle branches at once and both ventricles are working at the same time. When the signal goes down the right bundle branch a little slower than the left bundle branch, the right ventricle contracts later than the left one. This is what's going on when you have a right bundle branch block, and it happens because the signal has to go around a block in the branch.

Because the ventricles aren't working at exactly the same time, this creates an irregular heartbeat (arrhythmia.)

Right bundle branch block can be complete or incomplete. Unlike complete right bundle branch block, incomplete right bundle branch block doesn't increase your risk of heart attack and death.

Who does right bundle branch block affect?

Right bundle branch block can happen in healthy people. It's more likely to happen in older people.

Symptoms and Causes

What are the symptoms of right bundle branch block?

You most likely won't have any symptoms.

What causes right bundle branch block?

There are several causes of right bundle branch block, including:

- Myocarditis.
- Trauma to your chest.
- Heart attack (myocardial infarction).
- Right heart catheterization or other procedures.
- Changes in branch structure, such as stretching.
- Diseases (like Lev's disease or Lenegre's disease).

Diagnosis and Tests

How is right bundle branch block diagnosed?

A provider often finds it during an annual physical.

What tests will be done to diagnose right bundle branch block?

Your healthcare provider will review your electrocardiogram (EKG) results carefully to make sure you don't have a different problem, such as:

- Ventricular tachycardia.
- Brugada syndrome.
- Incomplete left bundle branch block.

Management and Treatment

How is right bundle branch block treated?

Usually, if you don't have symptoms and you don't have heart disease, you don't need treatment for right bundle branch block.

Outlook / Prognosis

What can I expect if I have right bundle branch block?

Right bundle branch block may stay the same without any change or the block may progress to involve other conduction branches.

How long does right bundle branch block last?

Right bundle branch block doesn't go away.

What is the outlook for right bundle branch block?

Your outlook depends on whether you have cardiovascular disease. If you don't have heart disease, having right bundle branch block doesn't change your life expectancy or add to your risk level. But having right bundle branch block can put you at a higher risk of death if you also have heart failure or a heart attack.

Living With

How do I take care of myself with right bundle branch block?

If you don't have symptoms and you don't have heart disease, you don't need to do anything for right bundle branch block. But if you've had other problems like a heart attack or heart failure, you need to continue with treatment for those issues.

When should I see my healthcare provider?

You should see your provider if you have other heart problems in addition to right bundle branch block.

When should I go to the ER?

You should go to the ER if you think you're having a heart attack.

- What caused my right bundle branch block?
- What can I do to keep my heart failure from getting worse?
- How can I take care of myself after a heart attack?

Additional! Common Questions

How common is a right bundle branch block?

Many people have right bundle branch block, especially as they age. About 11% of people have this by the time they're 80.

How serious is a right bundle branch block?

If you have no symptoms and no heart disease, a right bundle branch block is not serious. But if you've already had heart failure or a heart attack along with right bundle branch block, it puts you at a higher risk of death.

Is right bundle branch block permanent?

Yes.

Right bundle branch block isn't a cause for worry if you don't have symptoms or heart disease. But when you have right bundle branch block and you've already had a heart attack or heart failure, you should focus on continuing with treatment for those problems. Be sure to follow your provider's treatment plan for the best results.

Last reviewed on 08/09/2021.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)



[heart.org/en/health-topics/cardiomyopathy/what-is-cardiomyopathy-in-adults/transthyretin-amyloid-cardiomyopathy-attr-cm](https://www.heart.org/en/health-topics/cardiomyopathy/what-is-cardiomyopathy-in-adults/transthyretin-amyloid-cardiomyopathy-attr-cm)

December 8, 2021

What is transthyretin amyloid cardiomyopathy?

Transthyretin (trans-thy-re-tin) amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease of the heart muscle. In ATTR-CM, a protein called transthyretin that normally circulates in the bloodstream becomes misshapen and builds up in the heart, nerves and other organs.

When these amyloid deposits build up in the heart, the walls can become stiff, making the left ventricle unable to properly relax and fill with blood. This is called cardiomyopathy. As the condition progresses, the heart can become unable to adequately squeeze to pump blood out of the heart, ultimately leading to heart failure. There are two types of ATTR-CM – hereditary ATTR-CM (hATTR-CM) and wild-type ATTR-CM (wATTR-CM).

Hereditary ATTR-CM

In hereditary ATTR-CM, which can run in families, there's a variant in the transthyretin gene, which results in amyloid deposits in the heart, nerves and sometimes the kidneys and other organs. Symptoms may start as early as 30, although most present later in life.

Hereditary ATTR-CM is more common in localized parts of Portugal, Brazil, Sweden and Japan; however, there are a number of variants in different parts of the world. Some variants are more common in people of Irish ancestry while others are common among people of African descent.

Different variants may progress in a different way and involve different organs. The most common variant in the United States occurs in 3-4% of all Blacks.

Genetic testing may provide important information to developing a treatment plan.

Wild-type ATTR-CM

In the wild-type ATTR-CM (wATTR-CM), there is no variant in the transthyretin gene. Wild-type ATTR-CM doesn't run in families. It most commonly affects the heart and can also cause carpal tunnel syndrome and pain and numbness in the hands and feet, called peripheral neuropathy. Recent data suggests lumbar spine involvement and forearm tendon rupture may precede cardiac involvement. The disease most often occurs in elderly men.

Getting support for you and your caregivers is important to your health. Research shows that going it alone and not seeking support during a heart diagnosis can reduce your ability to make the lasting changes you need to live a longer, healthier life.

Last Reviewed: May 29, 2024

EXHIBITS

LAW Library Closures

I have
Zero Counsel
or Help

MBF

9-10-2025

RJD - Law Library C-yard

INMATE REQUEST FOR INTERVIEW

DATE	TO	FROM (LAST NAME)	CDCR NUMBER
9-10-2025		Mr Fields	V-46240
HOUSING	BED NUMBER	WORK ASSIGNMENT	JOB NUMBER
C-14	230	Groups	FROM TO
OTHER ASSIGNMENT (SCHOOL, THERAPY, ETC.)			ASSIGNMENT HOURS
			FROM TO

Clearly state your reason for requesting this interview.

You will be called in for interview in the near future if the matter cannot be handled by correspondence.

I had "Preferred Legal user" up till September 4-2025 - Law Library was closed ~~Sept 3~~ September 3-2025 - RJD Down Day and closed September 5-2025 Friday - I have pending U.S.D.C Verifiable - with two loss's in U.S.D.C - I now in S.C.O.U.T.S and

in U.S.CA 9th due to - me Prisoner / staff communication Rymthem Please explain below

Do NOT write below this line. If more space is required, write on back.

INTERVIEWED BY

A. WILLIAMS

DATE

SEPT 3

DISPOSITION

LIBRARY C WAS CLOSED DUE TO STAFF TRAINING

LOW STAFFING ON SEPT. 5

50 + Can send to

STATE OF CALIFORNIA
GA-22 (Rev. 2013-10)

DEPARTMENT OF CORRECTIONS & REHABILITATION

INMATE REQUEST FOR INTERVIEW

DATE	TO	FROM (LAST NAME)	CDCR NUMBER
Aug-12-2025	C-Law Library	Mr FIELDS	V-46240
HOUSING	BED NUMBER	WORK ASSIGNMENT	JOB NUMBER
C-14	230	EOP	FROM TO
OTHER ASSIGNMENT (SCHOOL, THERAPY, ETC.)			ASSIGNMENT HOURS
			FROM TO
			GROUPS

Clearly state your reason for requesting this interview.
You will be called in for interview in the near future if the matter cannot be handled by correspondence.

I need ~~for~~ the reason stating why on August 6-2025
due to No fault of my prisoners own -

Thank you

Do NOT write below this line. If more space is required, write on back.

INTERVIEWED BY

A. WILLIAMS

DATE

8/11/2025

DISPOSITION

ALL INFORMATION WILL BE CLOSED 8/16/2025 DUE TO STAFF TRAINING.

INMATE REQUEST FOR INTERVIEW

DATE	TO	FROM (LAST NAME)		CDCR NUMBER
July 25-2025		Mr FIELDS		V-46246
HOUSING	BED NUMBER	WORK ASSIGNMENT	JOB NUMBER	
C-14	230	EOP	FROM — TO	
OTHER ASSIGNMENT (SCHOOL, THERAPY, ETC.)			ASSIGNMENT HOURS	
Groups			FROM — TO	

Clearly state your reason for requesting this interview.
You will be called in for interview in the near future if the matter cannot be handled by correspondence.

I need the documentation or reason why RJD-C-yard
Law Library - ~~was~~ closed after only being open ~~at~~ approx-
imately 1 hour

Do NOT write below this line. If more space is required, write on back.

INTERVIEWED BY

A. WILLIAMS

DATE

7/25/2025

DISPOSITION

LIBRARY CLOSED 7/23/2025 DUE TO STAFF TRAINING REBAPT 2W

INMATE REQUEST FOR INTERVIEW

DATE		TO		FROM (LAST NAME)		CDCR NUMBER	
July-16-2025		RJD - C-yard Library		Mr. Fields		V-46240	
HOUSING	BED NUMBER	WORK ASSIGNMENT		JOB NUMBER			
C-14 -	230			FROM		TO	
OTHER ASSIGNMENT (SCHOOL, THERAPY, ETC.)				ASSIGNMENT HOURS			
				FROM		TO	

Clearly state your reason for requesting this interview.
You will be called in for interview in the near future if the matter cannot be handled by correspondence.

This is documentation. The RJD-yard Law Library was
closed from this date below till now

Do NOT write below this line. If more space is required, write on back.

INTERVIEWED BY

A. WILLIAMS

DATE

7/16/2025

DISPOSITION

LIBRARY WAS CLOSED ACCORDING TO PR SCHEDULE

**JUNE/JULY
2025**

PSR HIGHLIGHTS

- **MASS CELL SEARCHES – FACILITY C: JUNE 23**
- **COMMON AREA SEARCHES FACILITY A (JUNE 21)**
- **COMMON AREA SEARCHES FACILITY C (JUNE 22)**
- **PSR CLOSURE: WEDNESDAY, JULY 2, 2025 AT 1600 HOURS**
- **NORMAL PROGRAM ON ALL FACILITIES: JULY 2, 2025 AT 1600 HOURS**

SYNOPSIS OF DAILY PROGRAM UNDER PSR

and for excising corrupt union officials from positions of leadership. The deterrent power of RICO enforcement over time should produce a more viable, democratically elected union leadership. 82 footnotes.

Additional Details

Publication Format: Article
Publication Type: Legislation/Policy Analysis
Language: English
Country: United States of America

Downloads

No download available

Availability

[Find in a Library](#)

Popular Topics [🔗](#)

[Labor racketeering](#) [Legislative impact](#) [Organized crime](#)

[Racketeer Influenced and Corrupt Organizations \(RICO\) Act](#)



U.S. DEPARTMENT OF JUSTICE
OFFICE OF JUSTICE PROGRAMS

**SUPREME COURT OF THE UNITED STATES
OFFICE OF THE CLERK
WASHINGTON, DC 20543-0001**

July 31, 2025

Marcus Brent Fields
V-46240
480 Alta Road
San Diego, CA 92179

RE: Letter

Dear Mr. Fields:

In reply to your letter or submission, received July 31, 2025, I regret to inform you that the Court is unable to assist you in the matter you present.

Under Article III of the Constitution, the jurisdiction of this Court extends only to the consideration of cases or controversies properly brought before it from lower courts in accordance with federal law and filed pursuant to the Rules of this Court. The Court does not give advice or assistance or answer legal questions on the basis of correspondence.

Your papers are herewith returned.

Sincerely,
Scott S. Harris, Clerk
By:

Angela Jimenez
(202) 479-3392

Enclosures

Mr Marcus Brent Fields

RJD - C-14-230

480 Alta Road

San Diego, CA, 9

92179

ATTN CLERK

New

The Supreme Court of
The United States

Marcus Brent Fields

Plaintiff

V.

Pfizer Inc. Albert Bourla CEO
Drew Weissman, Covid-19 mRNA
inventor • Katalin Kariko Bio-N-Tech
bio-chemist • John and Jane Doe
Scientist, Chemist - Physicist
Ugar Shahin Bio-N-Tech CEO

Defendants

(Pro-SE) Last Mediation Motion

- ① Pro-SE Plaintiffs Last
Attempt with Defendants -
before I file my writ of
Certiorari - for one hundred
million dollars Flat Defend-
ants Pfizer Inc. one time offer
stemming from ^{to resolve} case U.S. CA-2nd
Circuit # 24-2735
- ② Proof of Service

To: Supreme court of the United States - I plaintiff Mr Marcus
Brent Fields for my last (Pro-SE) mediation Attempt - I will settle
out of court for one Hundred million dollars Flat Placed on my prison
Personal account within 30 days ~~of the attempt~~ For the
destruction of my heart and vital organs - Pains and sufferings
- After Taxes - ~~and~~ your counsel can visit or Attorney Zoom
RJD "Public Relations office" one time offer to contact me on
this document

RECEIVED

JUL 31 2025

OFFICE OF THE CLERK
SUPREME COURT, U.S.

Sincerely
Mr Marcus Fields
(Pro-SE)

[Signature]
July-20-2025

No. _____

IN THE
SUPREME COURT OF THE UNITED STATES

Marcus Brent Fields — PETITIONER
(Your Name)

VS.

Pfizer Inc et al — RESPONDENT(S)

PROOF OF SERVICE

I, Marcus Brent Fields, do swear or declare that on this date, _____, 20____, as required by Supreme Court Rule 29 I have served the enclosed MOTION FOR LEAVE TO PROCEED *IN FORMA PAUPERIS* and PETITION FOR A WRIT OF CERTIORARI on each party to the above proceeding or that party's counsel, and on every other person required to be served, by depositing an envelope containing the above documents in the United States mail properly addressed to each of them and with first-class postage prepaid, or by delivery to a third-party commercial carrier for delivery within 3 calendar days.

The names and addresses of those served are as follows:

— Supreme court of the united states
~~State of Texas, County of Harris, City of Houston~~

I declare under penalty of perjury that the foregoing is true and correct.

Executed on September 3, 2025

Matted

~~Matt B Fields~~ 9-10-2025

Marcus B Fields
(Signature)

U.S. CA - For 2nd circuit

EXHIBITS

M.B.K.
9-10-2028

CASE LAW Supreme Court Pfizer Inc

Appellate Review - Firestone Tire and Rubber Company v Risjord
449 U.S. 368, 375, 101 S.Ct. 669, 66 L.Ed. 2d 571 (1981)

To fall within the collateral-order doctrine, an order must 'conclusively determine the disputed question, resolve an important issue completely separately from the merits of the action, and be effectively unreviewable on appeal from final judgment.'

- Mitchell v Forsyth, 472 U.S. 511, 527, 105 S.Ct. 2806, 86 L.Ed. 2d 411 (1985) - A decision is appealable

- Will v Hallock, 546 U.S. 345, 349, 126 S.Ct. 952, 163 L.Ed. 2d 836 (2006) - To warrant review under the collateral order doctrine. The order must 1 - 2 - 3

Clearly established

- ELDER v HOLLOWAY, 510 U.S. 510, 514, 516, 114 S.Ct. 1019, 127 L.Ed. 2d 344 (1994) - whether a federal right was clearly established is a question of law that is reviewed de novo - Appellate court should use all relevant precedents, not just those presented in district courts by the parties

- Taylor v Barkes, 575 U.S. 135 S.Ct. 2042, 2044, 192, L.Ed. 2d 78 (2015) - Pfizer defendants knew they were breaking the law and understood no warning on their covid-19 vaccine to no one which would make clear through their greed they [their] actions violated the law

- Rizzo v. Goode, 423 U.S. 362, 371-72, 377, 96 S.Ct. 598, 46 L.Ed. 2d 561 (1976)
Constitutional claim under 42 U.S.C. § 1983 a plaintiff must show an affirmative link between the alleged injury and the conduct of the individual defendant

① - The Pfizer defendants violated my constitutional rights ② The 5 Pfizer Inc. Defendants et al ③ Defendants product covid-19 vaccine I was given on March 4, 2021 EAU only approved - No warnings labels - Destroyed my heart more - Left me in pain - and close to sudden death & EKE wise and still in pain to this day -

CASE LAW Supreme Court Pfizer Inc.

- CONSPIRACY - ADICKES V. S.H. KRESS and CO., 398 U.S. 144, 150-52, 90 S.Ct. 1598, 26 L.Ed.2d 142 (1970)
 - I plaintiff will prove in documents or trial Pfizer Inc et al defendants were acting under color of state law ~~to~~ 'reached an understanding' to deprive me of my constitutional rights
- Anderson V Liberty Lobby, Inc., 477 U.S. 242, 249, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986) - An allegation of conspiracy can only be overcome at summary judgment when the moving parties' submissions foreclose [the possibility of existence of certain facts from which] it would be open to a jury... to infer from the circumstances that there had been a meeting of the minds.
- First Amendment - ELROD V Burns, 427 U.S. 347, 373, 373 S.Ct. 2673, 49 L.Ed.2d 547 (1976): [T]he loss of first amendment freedoms, for even minimal periods of time, unquestionably constitutes irreparable injury.
- The ~~Pfizer~~ Pfizer covid-19 vaccine Lot "EN-6204" was also not covered under the Vaccine Act Section 2101 of the public health service ACT (42 U.S.C. - section 300 at established
- Private citizen can be held liable under 1983 - Beedle V ~~Wison~~ Wison, 422 F.3d 1059 (CA10 2005) was a willfull participant in joint action with the state or it's agents
"Dennis V Sparkab" 449 U.S. 24, 27, 101 S.Ct. 183, 66 L.Ed.2d 185 (1980)
- Lawsuit in Personal capacity - Hafer V Melo, 502 U.S. 29, 116 E.Ed.2d 301, 112 S.Ct.
- Cruel and unusual Punishment - History - Ingraham V Wright 403 U.S. 669, 51 L.Ed.2d 711, 997 S.Ct. 1401 (1973)

CASE LAW Supreme Court Pfizer

- Misconduct in office - corrupt misbehavior by an officer in the exercise of the duties of the office or while acting under the color of office, 185 A.2d 45, 47 includes any act or omission in breach of duty of public concern by one who has accepted public office. 318 A.2d 783, 786 - see bribery

- Bilateral contract - one in which there are mutual promises between two parties to the contract, each party being both a promiser and a promisee, Corbin Contracts § 21 (one-sided 1952)

- Hindsight analysis - Recognition of the nature requirements of a situation or event after the occurrence. generality = undetailed statement.

- Defendants violations - with support words & case law

- Indemnity - shifting defendants distinction between primary and secondary liability

- medical malpractice - delay and diagnosis - informed consent - Improper treatment - "drug side effects" - Nursing errors

- Preponderance = more likely than Not

- A theory - To ATTR-CM one or both of two types especially under diagnosed cause of heart failure.

- Policy 11th amendment - qualified Immunity, but should not have immunity - which violated my procedural Rights and constitutional violations -

~~Arrested by police on 10/2/2006 at 10:30 AM~~

- Aiding and abetting U.S. v. Serrano 434 F.3d 1003 (7th Cir. 2006)
Federal crimes of aiding and abetting requires knowledge of illegal → activity that is being Aided and abetted - desire to help it succeed, and some act of helping

D.E.A - LAW Pfizer Defendants Violations

In *Fields v Pfizer et al* U.S.C.A - 2nd cir Docket # 24-2735
Defendants - Pfizer Inc Albert Bourla CEO • Drew Weissman
COVID-19 mRNA Inventor, Katalin Kariko, Bio-N-Tech, Bio-Chemist,
John and Jane Does, Scientist-Chemist-Physicist, Ugur Sahin, Bio-N-
Tech C.E.O., Defendants -

§§ 801-971 - Control and enforcement (801-904) Registration of
Manufacturers Distributer

21 U.S.C.S § 824

Denial, revocation, or suspension of registration

(a) Grounds - A registration pursuant to section 303 [21 USC § 823]
to manufacture, distribute, or dispense a controlled substance or a list
1 chemical may be suspended or revoked by the Attorney General upon
finding the registrant (i) has materially falsified any application filed
pursuant to or required by this title or title II:

XX (4) has committed such acts as would render his registration under section
303 [21 USC § 823] inconsistent with the public interest as determined
under such section = A registration pursuant to section 303(h)(b) limits
of revocation or suspension (E) service to show cause order: ~~Record~~ Proceedings:
(1) registration under section 303 [21 USC § 823] - The Attorney General
shall serve upon the applicant or registrant an order to show cause
why registration should not be denied, revoked or (2) A order to
show cause under paragraph (1)(A) contain a statement of the basis
for the denial, revocation, or suspension, including specific citations
to any law or regulation alleged to be violated by the applicant/registrant

21 U.S.C.S. 823

(g) Research by Practitioners, Pharmacies, research applications - construction
of Article 7 of convention of Psychotropic substances (1)(A)(B)(C)(D)(E) =
Such other conduct which may threaten the Public health or
safety - separate registration under this part [21 USC § 821 et seq]
who are already registered under this part 21 U.S.C. § 821 (2)(A)
Research with controlled substances on schedule I shall be
referred to the secretary who shall determine the qualifications
and competency of each practitioner requesting registration, as well
as the merits of the Research

FEDERAL TRADE COMMISSION VIOLATIONS

- By Pfizer Defendants - Albert Bourla, CEO, Drew Weissman, COVID-19 mRNA Inventor, Katalin Kariko, Bio-N-Tech Bio-Chemist, John and Jane Does, Scientist, Chemist, Physicist, Umar ~~S~~ Sahin, Bio-N-Tech CEO

- I. Investigative Authority A. In General -

The commission may "Prosecute any inquiry necessary to it's duties in any part of the United States" FTC Act SEC. 3, 15 U.S.C. SEC. 43 and is authorized "to gather and compile information concerning, and to investigate from time to time the organization = Pfizer Inc Defendants' business, conduct, practices, and management of any person, partnership, or corporation, engaged in or whose business, ~~conduct, practices, and~~ affects commerce, excepting banks, savings and loan institutions"

- B. Specific Investigative Powers

The commission's specific investigative powers are defined in sections 6, 9, and 20 of the FTC Act, 15 U.S.C. secs. 46, 49 and 57b-1 which authorizes investigations and various forms of compulsory process.

FTC DEALER - Section 9 of the FTC act authorizes the commission to require by Subpoena the attendance and testimony of witnesses and the production of all such documentary evidence relating to any matter under investigation * 15 U.S.C. SEC 49.

- If a party fails to comply with a subpoena, the commission may seek enforcement of the subpoena in "any of the district courts of the United States"

- "The Bureau of competition" routinely use's subpoena provisions of section 9 to investigate alleged "unfair methods of competition" and other "antitrust violations"

- Section 6(b) of the FTC ACT -

Section 6 of the FTC ACT provides another investigative tool. section 6(b) empowers the commission to require an entity to file "annual or special... reports or answers in writing to specific questions ^{to provide} ~~about the~~ information about the entity's organization, in this case Pfizer 15 U.S.C. SEC. 46(b) - 6(b)

(2)

Federal TRADE Commission violations of Defendants' contr

3. section 6(f) and section 21 of the FTC Act -

It also authorizes the agency to share confidential information with other appropriate enforcement agencies - section 21, 15 U.S.C. Sec. 57b-2 establishes the conditions and procedures for confidential treatment of various types of materials and information obtained by the commission

7. International Investigations

under the International Antitrust Enforcement Assistance Act ("IAEAA"), 15 U.S.C. Secs. 6201 et seq., the F.T.C. may invoke all of its investigative tools to obtain materials or information from domestic sources for the use of foreign antitrust authorities, and may seek investigative assistance from those authorities, from antitrust matters, pursuant to mutual or bilateral assistance agreements established under IAEAA, FTC Act sections 6(i) and 20(a)(8)(C), 15 U.S.C. - Secs. 46(i) and 57b-1(a)(8)(C), incorporate the IAEAA investigative authority into the FTC Act

- The undertaking spam, spyware, and Fraud Enforcement with Enforcers beyond Borders Act of 2006 (the "U.S. SAFE WEB Act of 2006 or 'Safe web'") (Pub. L. No. 109-455, extended by Pub. L. 112-203) added subsection (i) to section 6, allowing the Commission to use all its investigative powers to conduct investigations and discovery to help foreign law enforcement agencies in appropriate consumer protection matters. Section 6(j)(4), 15 U.S.C. Sec 46(j)(4), authorizes the commission, with the approval of the Secretary of State, to negotiate and conclude international agreements in the name of the United States or the commission if foreign law requires an agreement as a condition for reciprocal assistance or information sharing. Safe web amended section 6(f) and 21(b), 15 U.S.C. Secs. 46(f) and 57b-2(b), to authorize disclosure of confidential material or information to foreign law enforcement agencies in consumer protection matters, subject to appropriate confidentiality constraints

3

Federal Trade Commission - Violations of Defendants cont.

- Enforcement Authority

- Following an investigation, the commission may initiate an enforcement action using either an administrative or judicial process if it has "reason to believe" that the law is being violated

- I Consumer Protection

Section 5(a) of the FTC Act provides that "unfair or deceptive acts or practices in or affecting Commerce" are declared unlawful. "15 U.S.C. Sec. 45(a)(1)

- Deceptive Practices are defined in the commission's policy statement on deception as involving a material representation, omission or practice that is likely to mislead a consumer acting reasonably in the circumstances an act or practice is "unfair" if it "causes or is likely to cause substantial injury to consumers which is not reasonably avoidable by consumers themselves and not outweighed by countervailing benefits to consumers or to competition 15 U.S.C. Sec. 45(n) - unfair or deceptive section 5(a) = could be violations of trade regulation rule issued under section 18 of the F.T.C


- III Rulemaking Authority

The commission's rulemaking authority comes from section 6(g) of the FTC Act, 15 U.S.C. Sec. 46, which authorizes the commission "to make rules and regulations for the purpose of carrying out the provisions of this subchapter" See Nat'l Petroleum Refiners Ass'n v F.T.C., 482 F.2d 672, 693 (D.C. Cir. 1973); cert. denied, 415 U.S. 951 (1974) - (commission has authority to require octane labels on gasoline pumps) In 1975, section 18 of the F.T.C Act, 15 U.S.C. Sec. 57a became the commission's exclusive authority for issuing rules with respect to unfair or deceptive acts or practices under the F.T.C Act; section 6(g) continues to authorize these rules


(4)

Federal Trade Commission - Violations of Defendants Continued

- The Commission obtains such penalties by ~~bringing~~ filing a suit in federal district court under Section 5(m)(1)(A) of the FTC Act, 15 U.S.C. Sec. 45(m)(1)(A). In addition any person who violates a rule (irrespective of the state knowledge) is liable for injury caused to consumers by the rule violation. The Commission may pursue such recovery in a suit for consumer redress under section 19 of the FTC Act 15 U.S.C. Sec. 57b.
- Damages - Department of Justice - "may recover for injuries sustained by the United States Government [Treble damages] [§ 4A Clayton Act]"
- Private Parties may apply for Treble = equal triple damages [§ 4 Clayton Act]



- Document violations of law by defendants
- 42 U.S. Code 1320a-7a - civil monetary penalties -
(8)(2) Knowing makes, uses, or causes to be made or used, a false record or statement material to a false or fraudulent claim for payment for items and services furnished under a federal health program.



Defendants violations of "Universal Declaration of Human Rights"
Article 2, 3, 4, 5 no one shall be subjected to torture or to "cruel, inhuman or degrading treatment or punishment" 7 No discrimination
8, 9, 10 11 (1)(2)(12) up to (20)(1)(2) • Article 21 (1)(2)(3) • Article 22
Article 23 (1)(2)(3)(4) • Article 24 • Article 25 (1)(2) • Article 26 (1)(2)(3)
Article 27 (1)(2) • Article 28 • Article 29 (1)(2)(3)

I would like to file a claim Securities and Exchange Commission

Pfizer Said Covid-19 vaccine EAU was safe Lot# EN-6264

File a claim under Securities Exchange Act ~~10b~~
- section 10(b) and securities and exchange commission

Rule 10b-5 - Plaintiff must establish among other
elements, a material misrepresentation or omission -

Nguyen V Endologix inc. An omission is materially misleading
if there is a substantial likelihood that a reasonable investor
would view it as having significantly altered the total mix
of information that stockholders rely on to make investments

Retail : wholesale & Dept store union Loc. 338 Ret. Fund V

Hewlett-Packard Rule 10b-5 - Rule 10b-5 are heightened pleading
Requirements the complaint must state with Particularity the
misleading statement and the reason why the statement is
misleading -

- Pfizer Inc Defendants - Corporations - Associates Violations in case *Fidelis V Pfizer et al* - Albert Bourla CEO, Drew Weissman, Covid-19 mRNA Inventor, Katalin Kariko, Bio-N-Tech, Bio-Chemist, John and Jane Does, Scientist - Chemist - Physicist, Ugur Sahin Bio-N-Tech C.E.O (Defendants)

(Base erosion Profit shifting) tool enable corporates to achieve effective tax rates close to zero.

- Review any prior or current "Financial Secrecy Index" - world "offshore financial centre" and there "Regional Financial centres" - Review any all - Trust company Law, offshore insurance Laws, flags of current & prior.
- Convenience for shipping fleets and aircraft leasings, and beneficial regulations for on line services - Since 2004 the U.S. Congress stopped "Naked tax inversions" by U.S. corporations to corporate "merger inversions" started that involved moving to OECD tax havens.
- Example and fact - 2015 hybrid-tax inversion - intellectual property - AKA called leprechaun economics - U.S. - Treasury tighten there inversion rules ~~being~~ causing Pfizer to Abort their U.S. \$160 billion merger with Allergan. Plc.
- I can break down Pfizers (Financial Secrecy Index) "F.S.I" = There "Secrecy Jurisdiction" Governmental - Qualitative - qualitative and Political - (Pfizer Defendants never list members or each other)
- Non - Governmental - Quantitative equals ① Tax Rate ② Connections ③ Quantum - Focus on Profits shifted = equals my inquiries will include Pfizer Defendants "Proxy Indicators" - Sense check" and defendant's GDP - Per - capita Tables
- U.S. Dedicated entities "onshore" specialized haven with strong secrecy Laws U.S. (Delaware) - Jersey - Puerto Rico (U.S.) almost a corporate tax haven "Concession" by the U.S.
- I will need help a little to prove there Greed - Product manufacturing liability - Covid-19 vaccine mRNA defective surum that destroyed my heart and body - there Financial scale ① Banking data ② National account Data ③ Corporate Data.
- My Research - Not to rank U.S. Pfizers "ranking number" showed that U.S. Corporations shield over U.S. \$250 billion per annum from taxes Some built up offshore cash deposits of U.S. 1-2 trillion Since around 2004 - I can take Pro-SE Lead but I'll need account counsel

Continued on

- Pfizer Inc Defendants - corporations - Associates violations in case Fields v Pfizer et al - Albert Bourla CEO & Drew Weissman, Covid-19 - mRNA Inventor - Katalin Kariko, Bio-N-Tech, Bio-chemist, John and Jane Does, Scientist-chemist-Physicist, Ugar Sahin, Bio-N-Tech CEO. (Defendants)
- At Jury trial I believe I can Prove by piercing "Pfizers veil and defendants of there Defendants personal "Phantom corporate investment" greed (Foreign Direct Investment) - FDI - Artificially inflated by the BEPS Flows that Add to the Haves ~~to~~ GDP
- Intellectual Property" equals Pfizers CEO Defendants "Revaluing" it's cost dramatically at that time.
- Transparency. U.S. congress in 2010 Passed the "Foreign Account Tax Compliance Act (FATCA) - & To I.R.S the Names and Tax Identification Number (TIN) of any U.S. owner. FATCA also requires U.S. Citizens & green card Holders who have foreign Financial assets in excess of \$50,000 to complete a new Form 8938 to be filed with the 1040 tax Return starting with the fiscal year 2010 - which Defendants Albert Bourla - Drew Weissman - Katalin Kariko and Ugar Sahin did not do.

MEDICAL DOCTORS - Principles

- I. A physician shall be dedicated to providing competent medical care with compassion and respect for human dignity and rights
- II. A Physician shall uphold the standards of professionalism, be honest in all professional interactions, and strive to report physicians deficient in character or competence, or "engaging in fraud" or "deception" to appropriate entities
- III. A physician shall respect the law and also recognize a responsibility to seek changes in those requirements which are contrary to the best interests of the Patient
- IV. A physician shall respect the rights of patients, colleagues, and other health professionals, and shall safeguard patient confidences and privacy within the constraints of the Law
- V. A physician shall continue to study, Apply, and advance scientific knowledge, maintain a commitment to medical education, make relevant information available to patients, colleagues, and the Public, obtain consultation, and use the talents of other health Professionals when indicated.
- VI. A physician shall, in the provision of appropriate patient care, except in emergencies, be free to choose whom to serve, ~~with~~ whom to associate, and the environment in which to provide medical care
- VII. A physician shall recognize a responsibility to participate in activities contributing to the improvement of the community and the "betterment of Public Health"
- VIII. A physician shall while caring for a patient, regard responsibility to the patient as paramount
- IX. (A Physician shall support access to medical care for all people)

COVID-19 Vaccination Record Card

Please keep this record card, which includes medical information about the vaccines you have received.

Por favor, guarde esta tarjeta de registro, que incluye información médica sobre las vacunas que ha recibido.



Last Name Fidds First Name Marcus MI
 Date of birth 03/18/1976 Patient number (medical record or IIS record number) V46240

Vaccine	Product Name/Manufacturer Lot Number	Date	Healthcare Professional or Clinic Site
1 st Dose COVID-19	<u>Pfizer</u> <u>EN6204</u>	<u>03/21/21</u> mm dd yy	<u>RJD</u>
2 nd Dose COVID-19	<u>Pfizer</u> <u>FE3590</u>	<u>10/22/21</u> mm dd yy	<u>RJD</u>
Other		mm dd yy	
Other		mm dd yy	

COVID-19 Vaccination Record Card

Please keep this record card, which includes medical information about the vaccines you have received.

Por favor, guarde esta tarjeta de registro, que incluye información médica sobre las vacunas que ha recibido.



Last Name Fidds First Name Marcus MI
 Date of birth 3/18/76 Patient number (medical record or IIS record number) V46240

Vaccine	Product Name/Manufacturer Lot Number	Date	Healthcare Professional or Clinic Site
1 st Dose COVID-19	<u>Pfizer</u> <u>EN6204</u>	<u>3/4/21</u> mm dd yy	<u>RJD</u>
2 nd Dose COVID-19		mm dd yy	
Other		mm dd yy	
Other		mm dd yy	

Exh. b. 4

~~Provide a statement that identifies the relevant facts and makes a showing of likely merit as to each issue, not intend to present on appeal - See Local Rule 24.1~~

- ① my documented bad heart condition my Pains I be in before and after Defendants Product: Pfizer's Defective Design - Covid-19 Vaccine Lot # EN-6204
- ② Lower Court & Defendants Violated my rights & U.S. Constitutional Law Violations of 1st - 6th - 8th - 13th and 14th Amendment "cruel and unusual Punishment"
- ③ Title 11.6, my Civil rights Disability right
- my universal declaration of human Rights
- ④ Product manufacturing Liability
- No warning on major - Adverse Negative side effects of mRNA vaccines
- Long Lingering for anyone especially me an African - American
All Defendants I'll Prove Knew it was super experimental especially at start.
- ⑤ — Science Proves Pfizer Defendants were aware of the Known and Unknown Dangers of this vaccine and avoided - denied - deflected - and Perjured themselves by down Playing the numbers — Percentages of the bad negative of this covid-19 vaccine effect on - This Product.
- ⑥ I Plaintiff - Demand for Jury trial" - where for my health treatment and monetary reliefs for my "unknown" maybe forever Pain(s) which include but not limited to ~~10~~ my heart - chest Pains, Headachs - dizzy spells - numbness in leg - mental anguish, Anxiety, Depression ~~heightened now~~ due to defendants avoidance - deflection
- ⑦ Pfizer Inc & Bio - N - Defendants Violations which will include but not limit Laws, Nelson Mandela Rules Rules for the treatment of Pri. Violations For "Profit" Greed, Securities and exchange Commission - Federal Trade Commission,

EVEN A Pri

I AM A Human being.

Respectfully
Submitted
Pro-SE
M Fields

9-10-2025 ~~2024~~

FIELDS - Personal Search For Civil Counsel

I received No Response or Zero help

Date

3-25-2024 - The DeRubestis Law Firm - Susan Rubenstein & P Goldman
3-25-2024 - Kirkland & Ellis LLP - Attorney Mark Holischer
3-25-2024 - Kabateck LLP - Attorney Brian S Kabateck

Aug-2022 Dorick Law Firm

Aug-3-2022 - mailroom issues with C.D.-CA - I wrote U.S.P.S. Postmaster General
Louis DeJoy

Nov-11-2022-2023 - IVE McNeill, Wyatt, Purcell & Diggs

Aug-29-2023 Law Offices of John Burton

Aug-21-2022 ACLU of Southern California

Aug-21-2023 ACLU Legal Director Steven Shapiro N.Y.

8-24-2022 Lance R Stone - medical malpractice

11-27-2023 Attorney Knobbe Martens - Attorney Brian Horne partner

AM Jnt

9-10-2025



PRIMER *Exhibit (5)*

**U.S. Department of Justice
Civil Rights Division**

Washington, DC 20530

August 25, 2023

Macus Fields, #V046240
480 Alta Road
San Diego, CA 92179

Dear Macus Fields, #V046240,

Thank you for your letter on November 7, 2022. Your report number is 336752-RZZ. Please refer to it if you write us in the future. This letter will tell you how the Special Litigation Section will review your report and what other options you may choose to pursue.

The Special Litigation Section only handles cases that arise from widespread problems that affect groups of people. We do not assist with individual problems, except as noted below. In general, we cannot help you recover damages or any personal relief. Nor can we assist in criminal cases, including wrongful convictions, appeals or sentencing. We also cannot assist with issues involving federal facilities or federal officials.

There are only two areas in which the law allows us to investigate and address individual incidents:

- if you are being prevented from practicing your religion in a prison, jail, mental hospital or other facility operated by or for a state or local government; or
- if you have encountered a physical obstruction or experienced force or the threat of force when accessing a reproductive health care facility or religious institution.

Each week, we receive many reports of potential violations. We analyze this information to help us select new cases or pursue existing cases. We will review your letter to see if it fits into one of these two categories. If so, we may contact

you for additional information. If not, we will not contact you as unfortunately, we do not have the resources to follow up on every letter.

The Special Litigation Section protects the civil rights of:

- people in state and local correctional facilities and institutions for people with disabilities
- people when they interact with state and local law enforcement agencies
- children in the administration of juvenile justice
- people who confront a physical obstruction, force or the threat of force when they seek access to reproductive health care clinics or religious institution
- people seeking to practice their religion while in state and local institutions
- people with disabilities seeking to receive needed services in integrated, community settings

For more information about the Special Litigation Section, please visit our web page: <https://www.justice.gov/crt/about/spl/> (<https://www.justice.gov/crt/about/spl/>). If your concern is outside our area, you may wish to consult the Civil Rights Division web page to find the correct section: <https://civilrights.justice.gov/> (<https://civilrights.justice.gov/>).

If we are unable to help, you may wish to consult a private attorney or a legal aid organization for assistance. Thank you again for contacting the Special Litigation Section.

Sincerely,

U.S. Department of Justice

Civil Rights Division



Pfizer *Exhibit C*

**U.S. Department of Justice
Civil Rights Division**

Washington, DC 20530

October 2, 2023

Marcus Fields #V-46240

P.O. Box 290066

Reprea, CA 95671

Dear Marcus Fields #V-46240,

Thank you for your letter on April 13, 2023. Your report number is 291207-ZZN. Please refer to it if you write us in the future. This letter will tell you how the Special Litigation Section will review your report and what other options you may choose to pursue.

The Special Litigation Section only handles cases that arise from widespread problems that affect groups of people. We do not assist with individual problems, except as noted below. In general, we cannot help you recover damages or any personal relief. Nor can we assist in criminal cases, including wrongful convictions, appeals or sentencing. We also cannot assist with issues involving federal facilities or federal officials.

There are only two areas in which the law allows us to investigate and address individual incidents:

- if you are being prevented from practicing your religion in a prison, jail, mental hospital or other facility operated by or for a state or local government; or
- if you have encountered a physical obstruction or experienced force or the threat of force when accessing a reproductive health care facility or religious institution.

Each week, we receive many reports of potential violations. We analyze this information to help us select new cases or pursue existing cases. We will review your letter to see if it fits into one of these two categories. If so, we may contact

you for additional information. If not, we will not contact you as unfortunately, we do not have the resources to follow up on every letter.

The Special Litigation Section protects the civil rights of:

- people in state and local correctional facilities and institutions for people with disabilities
- people when they interact with state and local law enforcement agencies
- children in the administration of juvenile justice
- people who confront a physical obstruction, force or the threat of force when they seek access to reproductive health care clinics or religious institution
- people seeking to practice their religion while in state and local institutions
- people with disabilities seeking to receive needed services in integrated, community settings

For more information about the Special Litigation Section, please visit our web page: <https://www.justice.gov/crt/about/spl/> (<https://www.justice.gov/crt/about/spl/>). If your concern is outside our area, you may wish to consult the Civil Rights Division web page to find the correct section: <https://civilrights.justice.gov/> (<https://civilrights.justice.gov/>).

If we are unable to help, you may wish to consult a private attorney or a legal aid organization for assistance. Thank you again for contacting the Special Litigation Section.

Sincerely,

U.S. Department of Justice
Civil Rights Division

To: Chief Civil Rights unit - Oct-27-2022

My name is Marcus Fields #V-46240 a California state Prisoner. Today I Just received a letter from U.S.D.C. S.D.N.Y. transferring my case back to California. # 1:22-cv-07971-UA. I am a prisoner 'Pfizer' pharmaceutical, Covid-19 surem Vaccine destroyed my heart. That doesn't give them the right in avoidance/Accountability/compensation mRNA - was experament especially in 2021 and they are now on B.S. - from Pfizer. Center for Disease control and prevention to National Institute of Health - world Health organization to / from Wuhan Institute of Virology's - Dr Fauci back them I am in pain hurting - in prison on a wrongfull conviction 42 years in life been down 2 yrs. straight on a persons word no one died. I have no income my family's on a fixed income. I am in Ad-seg on alleged Battery on a prisoner, now I have no law library - my legal work I only received 4 folders / my research whole and all came to a halt my California # 42 use 1983 is Responsibility / Liability againts CP Gov G. Newsom - The one the U.S.D.C. S.D.N.Y. was against Pfizer for Product Liability ~~DEFE~~ Defective even if the first part of liability lies on California --- Pfizer to ~~hash~~ hash out I am no doctor but know my injury facts.

Thank you .

Marcus Fields #V-46240
RJD-Ad-seg- BB-214
480 Alta Road
San Diego, CA, 92174

Respectfully submit

October-27-2022

M Fields



Exhibit 7 Pfizer

Page 26

U.S. Department of Justice

United States Attorney
Southern District of New York

86 Chambers Street, 3rd Floor
New York, NY 10007

March 17, 2023

BY FIRST CLASS MAIL

Marcus Brent Fields
#V-46240
480 Alta Road
San Diego, CA 92179

Dear Mr. Fields:


We received your complaint dated October 27, 2022, alleging certain claims relating to the Pfizer vaccine. As the complaint reflects, you are already participating in lawsuits pending on the issues you raise in the complaint, including in the Southern District of New York. Accordingly, we cannot take any action with regard to your claims, and we are returning your complaint to you.

Please be advised that your letter or complaint to this Office has no effect on any statute of limitations that might apply to your claims. By filing a submission with this Office, you have not commenced a lawsuit or a legal or administrative proceeding, and this Office has not initiated a lawsuit or a proceeding on your behalf.

Sincerely,

DAMIAN WILLIAMS
United States Attorney for the
Southern District of New York

By:


DAVID J. KENNEDY
Co-Chief, Civil Rights Unit
Tel.: (212) 637-2733

24

Note

Received around end March 2023 at New Folsom ACSA - SA

5

Marcus Brent Fields # V-46240
RJD-C-14-230
480 Alta Road
San Diego, California
92179

Clerk: S.C.G.T.U.S.
Case: Fields V Pfizer et al
U.S.A.P.2 NO-24-2735

Supreme Court of the
United States

Marcus Brent Fields
Plaintiff
Petitioner
V
Pfizer Inc et al
Defendants

Motion(s)
① Lower courts (001015)
Appended dated April-17-
2025 and July 10th 2025
From the second circuit
Court of Appeals attached
to this document
Rule 14.1(i) - Per Rule 14.5
Motion
② Proof of Service
③ Defendants counsel served

To: Supreme Court of the United States - Clerk - I petitioner. Plaintiff
- Attached to this document 1 April 17-2025 mandate - dismissed.
document and 2nd document of July 10th-2025 reconsideration
en banc denied motion - A complete copy of - writ of certiorari - with
these documents was mailed to opposing counsel Pfizer Inc
Address ② Proof of Service - this document

Re-Mailed September 23-2025

Sincerely
Respectfully
Pro SE
Mr Fields

MANDATE

S.D.N.Y.—N.Y.C.
24-cv-6653
Swain, C.J.

United States Court of Appeals
FOR THE
SECOND CIRCUIT

At a stated term of the United States Court of Appeals for the Second Circuit, held at the Thurgood Marshall United States Courthouse, 40 Foley Square, in the City of New York, on the 17th day of April, two thousand twenty-five.

Present:

Raymond J. Lohier, Jr.,
Joseph F. Bianco,
Eunice C. Lee,
Circuit Judges.

Marcus Brent Fields,

Plaintiff-Appellant,

v.

24-2735

Pfizer Inc., et al.,

Defendants-Appellees.

Appellant, pro se, moves for leave to proceed in forma pauperis ("IFP"), a protective order, appointment of counsel, and a jury trial. Upon due consideration, it is hereby ORDERED that the motion for IFP status is DENIED and the appeal is DISMISSED because it "lacks an arguable basis either in law or in fact." *Neitzke v. Williams*, 490 U.S. 319, 325 (1989); *see also* 28 U.S.C. § 1915(e). It is further ordered that the remaining motions are DENIED as moot.

FOR THE COURT:


Catherine O'Hagan Wolfe, Clerk of Court

A True Copy

Catherine O'Hagan Wolfe, Clerk

United States Court of Appeals, Second Circuit

Catherine O'Hagan Wolfe



MANDATE ISSUED ON 07/17/2025

**UNITED STATES COURT OF APPEALS
FOR THE
SECOND CIRCUIT**

At a stated term of the United States Court of Appeals for the Second Circuit, held at the Thurgood Marshall United States Courthouse, 40 Foley Square, in the City of New York, on the 10th day of July, two thousand twenty-five.

Marcus Brent Fields,

Plaintiff - Appellant,

v.

Pfizer Inc., et al.

Defendants - Appellees.

ORDER



Docket No: 24-2735

Appellant, Marcus Brent Fields, filed a motion for panel reconsideration, or, in the alternative, for reconsideration *en banc*. The panel that determined the appeal has considered the request for reconsideration, and the active members of the Court have considered the request for reconsideration *en banc*.

IT IS HEREBY ORDERED that the motion is denied.

FOR THE COURT:

Catherine O'Hagan Wolfe, Clerk

24-2735

Marcus Brent Fields, V46240
Richard J. Donovan Correctional Facility
480 Alta Road
San Diego, CA 92179

Received
8-6-2025

24-2735

Marcus Brent Fields, V46240
Richard J. Donovan Correctional Facility
480 Alta Road
San Diego, CA 92179

Rec 6-30-2025

PUBLIC DOCKET FOR
United States Court of Appeals for the Second Circuit

Court of Appeals Docket #: 24-2735

Docketed: 10/17/2024

Case Name: Fields v. Pfizer

Status: Determined

Nature of Suit: 3550 PRISONER PET-Civil Rights

Appeal From: SDNY (NEW YORK CITY)

Fee Status: IFP Pending in USCA

Case Type Information

1. Prisoner
2. State
3. Civil Rights

Originating Court Information

District: SDNY (NEW YORK CITY): 1:24-cv-6653

Trial Judge: Laura Taylor Swain, Chief District Judge

Date Filed: 08/28/2024

Date Order/Judgment	Date Order/Judgment EOD	Date NOA Filed	Date Rec'd COA
09/11/2024	09/16/2024	10/09/2024	10/11/2024

Associated Cases

Party and Attorney Listing

MARCUS BRENT FIELDS
V46240,
Plaintiff - Appellant

Marcus Brent Fields
[Pro Se]
Richard J. Donovan Correctional Facility
480 Alta Road
San Diego, CA 92179

PFIZER INC.
Defendant - Appellee

Pfizer Inc.
[Pro Se]
66 Hudson Boulevard East
New York, NY 10007

ALBERT BOURLA, CEO
Defendant - Appellee

Albert Bourla
[Pro Se]
235 East 42nd Street
New York, NY 10017

DREW WEISSMAN, Covid-19 MRNA Inventor
Defendant - Appellee

KATALIN KARIKO, Bio-N-Tech, Bio-Chemist
Defendant - Appellee

JOHN AND JANE DOES, Scientist-Chemist-
Physicist
Defendant - Appellee

UGAR SAHIN, Bio-N-Tech C.E.O.
Defendant - Appellee

Marcus Brent Fields,

Plaintiff - Appellant,

v.

Pfizer Inc., Albert Bourla, CEO, Drew Weissman, Covid-19 MRNA Inventor, Katalin Kariko, Bio-N-Tech,
Bio-Chemist, John and Jane Does, Scientist-Chemist-Physicist, Ugar Sahin, Bio-N-Tech C.E.O.,

Defendants - Appellees.

Docket

LEGEND:
(R) - Restricted Document
(L) - Locked Document

Date Filed	Entry #	Public Docket Text
10/11/2024	1	NOTICE OF PRISONER APPEAL, with district court docket, on behalf of Appellant Marcus Brent Fields, FILED. [Entered: 10/17/2024 12:25 PM]
10/11/2024	2	DISTRICT COURT ORDER, dated 09/11/2024, RECEIVED. [Entered: 10/17/2024 12:29 PM]
10/11/2024	3	ELECTRONIC INDEX, in lieu of record, FILED. [Entered: 10/17/2024 12:36 PM]
10/11/2024	9	(L) MOTION, demand for jury trial, on behalf of Appellant Marcus Brent Fields, FILED. [Entered: 10/17/2024 01:40 PM]
10/17/2024	4	PRISONER APPEAL, on behalf of Appellant Marcus Brent Fields, received by 10/11/2024, OPENED. [Entered: 10/17/2024 12:43 PM]

Date Filed	Entry #	Public Docket Text
10/17/2024	5	INSTRUCTIONAL FORMS, to Pro Se Appellant Marcus Brent Fields, SENT. [Entered: 10/17/2024 12:53 PM]
10/17/2024	6	INSTRUCTIONAL FORMS, to Pro Se Appellee Albert Bourla SENT. [Entered: 10/17/2024 01:06 PM]
10/17/2024	7	NOTICE, to Pfizer Inc., regarding a corporation proceeding Pro Se, and requesting a response 30 days from the date of this letter, SENT. [Entered: 10/17/2024 01:16 PM]
10/17/2024	8	AUTHORIZATION FORM, REQUESTED. [Entered: 10/17/2024 01:22 PM] [Edited: 10/18/2024 08:48 AM]
10/17/2024	10	DEFECTIVE DOCUMENT, motion, demand for jury trial, at docket entry 9, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 10/17/2024 01:53 PM]
10/23/2024	11	NEW PARTY, Appellee Ugar Sahin, ADDED. [Entered: 10/23/2024 03:50 PM]
10/23/2024	12	CAPTION, added Appellee Ugar Sahin, AMENDED. [Entered: 10/23/2024 04:04 PM]
11/01/2024	13	NOTICE, to Appellee, for failure to file an appearance, SENT. [Entered: 11/01/2024 10:34 AM]
11/04/2024	14	ORDER, dated 11/04/2024, stating this appeal may be subject to dismissal by 11/25/2024, unless appellant Marcus Brent Fields, submits fee or moves for in forma pauperis, copy to pro se appellant, FILED. [Entered: 11/04/2024 04:20 PM]
11/04/2024	15	ORDER, dated 11/04/2024, stating this appeal may be subject to dismissal by 11/25/2024, unless appellant Marcus Brent Fields, submits form D-P, copy to pro se appellant, FILED. [Entered: 11/04/2024 04:29 PM]
11/04/2024	16	ORDER, dated 11/04/2024, stating this appeal may be subject to dismissal by 11/25/2024, unless appellant Marcus Brent Fields, submits an Acknowledgment and Notice of Appearance, copy to pro se appellant, FILED. [Entered: 11/04/2024 04:36 PM]
11/13/2024	17	(L) ACKNOWLEDGMENT AND NOTICE OF APPEARANCE, on behalf of Appellant Marcus Brent Fields, FILED. Service date 10/30/2024 by United States Mail. [Entered: 11/16/2024 09:55 PM]
11/13/2024	18	PRISON LITIGATION REFORM ACT AUTHORIZATION FORM, FILED. Service date 11/13/2024 by No Service. [Entered: 11/16/2024 09:58 PM]
11/13/2024	19	LR 31.2 SCHEDULING NOTIFICATION, on behalf of Appellant Marcus Brent Fields, informing Court of proposed due date 11/28/2024, RECEIVED. Service date 10/30/2024 by United States Mail. [Entered: 11/16/2024 10:00 PM]
11/13/2024	20	(L) MOTION, for extension of time, permission to mail on behalf of Appellant Marcus Brent Fields, FILED. Service date 10/30/2024 by United States Mail. [Entered: 11/16/2024 10:06 PM]
11/13/2024	21	(L) MOTION, to proceed in forma pauperis, on behalf of Appellant Marcus Brent Fields, FILED. Service date 10/30/2024 by United States Mail. [Entered: 11/16/2024 10:08 PM]

Date Filed	Entry #	Public Docket Text
11/13/2024	22	(L) FORM D-P, on behalf of Appellant Marcus Brent Fields, FILED. Service date 10/30/2024 by United States Mail. [Entered: 11/16/2024 10:10 PM]
11/13/2024	23	UNDELIVERABLE MAIL, for Appellee Albert Bourla to USCA from USPS, received on 11/13/2024, RECEIVED. [Entered: 11/16/2024 10:14 PM]
11/13/2024	25	PAPERS, Additional PLRA Form, RECEIVED. [Entered: 11/16/2024 10:42 PM]
11/14/2024	24	(L) MOTION, for jury trial, on behalf of Appellant Marcus Brent Fields, FILED. Service date 11/14/2024 by No Service. [Entered: 11/16/2024 10:40 PM]
11/18/2024	26	DEFECTIVE DOCUMENT, motion for jury trial, at docket entry 24, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 11/18/2024 01:42 PM]
11/18/2024	30	UNDELIVERABLE MAIL, for Appellee Albert Bourla to USCA from USPS, received on 11/18/2024, RECEIVED. [Entered: 11/25/2024 07:26 PM]
11/19/2024	27	DEFECTIVE DOCUMENT, the motion for extension of time, at docket entry 20, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 11/19/2024 11:27 AM]
11/19/2024	28	DEFECTIVE DOCUMENT, motion to proceed in forma pauperis, at docket entry 21, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 11/19/2024 11:34 AM]
11/22/2024	29	CERTIFIED PRISONER AUTHORIZATION FORM, dated 11/22/2024, to Richard J. Donovan Correctional Facility, In care of Warden, ISSUED. [Entered: 11/22/2024 12:26 PM]
11/27/2024	31	UNDELIVERABLE MAIL, for to USCA from USPS for Appellee Albert Bourla, received on 11/25/2024, RECEIVED. [Entered: 11/27/2024 11:39 AM]
12/02/2024	32	UNDELIVERABLE MAIL, for Appellee Albert Bourla to USCA from USPS, received on 12/02/2024, RECEIVED. [Entered: 12/03/2024 08:06 PM]
12/05/2024	33	MOTION, for assignment of pro bono counsel, on behalf of Appellant Marcus Brent Fields, FILED. Service date 11/25/2024 by United States Mail. [Entered: 12/06/2024 08:35 AM]
12/05/2024	34	MOTION, to proceed in forma pauperis, for jury trial, for extension of time on behalf of Appellant Marcus Brent Fields, FILED. Service date 11/24/2024 by United States Mail. [Entered: 12/06/2024 08:46 AM]
12/05/2024	35	ACKNOWLEDGMENT AND NOTICE OF APPEARANCE, on behalf of Appellant Marcus Brent Fields, FILED. Service date 11/24/2024 by United States Mail. [Entered: 12/06/2024 08:48 AM]
12/05/2024	36	FORM D-P, on behalf of Appellant Marcus Brent Fields, FILED. Service date 11/24/2024 by United States Mail. [Entered: 12/06/2024 08:50 AM]
12/10/2024	37	CURED DEFECTIVE DOCUMENT, motion, to proceed in forma pauperis, for jury trial, extension of time, at entry 34, on behalf of Appellant Marcus Brent Fields, FILED. [Entered: 12/10/2024 09:42 AM] [Edited: 12/10/2024 09:44 AM]

Date Filed	Entry #	Public Docket Text
12/13/2024	38	UNDELIVERABLE MAIL, for Appellee Pfizer Inc. to USCA from USPS, received on 12/13/2024, RECEIVED. [Entered: 12/16/2024 12:01 PM]
01/03/2025	39	TRUST ACCOUNT STATEMENT, on behalf of Appellant Marcus Brent Fields, FILED. Service date 12/09/2024 by U.S. Mail. [Entered: 01/06/2025 10:38 AM]
03/11/2025	40	NOTICE, Case Status, SENT. [Entered: 03/11/2025 05:00 PM]
04/08/2025	41	SUPPLEMENTARY PAPERS TO MOTION TO PROCEED IN FORMA PAUPERIS, FOR JURY TRIAL, FOR EXTENSION OF TIME, on behalf of Appellant Marcus Brent Fields, FILED. Service date 12/09/2024 by United States Mail. [Entered: 04/10/2025 06:52 PM]
04/15/2025	42	DEFECTIVE DOCUMENT, Form D-P, at docket entry 22, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 04/15/2025 12:35 PM]
04/15/2025	43	CURED DEFECTIVE DOCUMENT, Form D-P, at entry 36, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 04/15/2025 12:37 PM]
04/15/2025	44	DEFECTIVE DOCUMENT, Acknowledgment and Notice of Appearance Form, at docket entry 17, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 04/15/2025 12:43 PM]
04/15/2025	45	CURED DEFECTIVE DOCUMENT, Acknowledgment and Notice of Appearance Form, at entry 35, on behalf of Appellant Marcus Brent Fields, copy to pro se appellant, FILED. [Entered: 04/15/2025 12:44 PM]
04/17/2025	46	NEW CASE MANAGER, Khadijah Young, ASSIGNED. [Entered: 04/17/2025 01:51 PM]
04/17/2025	47	MOTION ORDER, denying motion to proceed in forma pauperis, denying as moot motions for a protective order, appointment of counsel, and a jury trial, on behalf of Appellant Marcus Brent Fields; and the appeal is dismissed, by RJL, JFB, ECL, copy to pro se appellant, FILED. [Entered: 04/17/2025 02:03 PM]
05/09/2025	48	(L) MOTION, for rehearing en banc, decrease in monetary damages, on behalf of Appellant Marcus Brent Fields, FILED. Service date 04/24/2025 by United States Mail. [Entered: 05/12/2025 03:58 PM] [Edited: 05/12/2025 04:19 PM]
05/12/2025	49	DEFECTIVE DOCUMENT, Motion for Rehearing en banc, decrease in monetary damages, at docket entry 48, on behalf of Appellant Marcus Brent Fields, FILED. [Entered: 05/12/2025 04:17 PM]
06/03/2025	50	MOTION, for reconsideration en banc, on behalf of Appellant Marcus Brent Fields, FILED. Service date 05/23/2025 by United States Mail. [Entered: 06/03/2025 02:34 PM]
06/03/2025	51	MOTION, for permission to add exhibits to motion for reconsideration en banc, on behalf of Appellant Marcus Brent Fields, FILED. Service date 05/23/2025 by United States Mail. [Entered: 06/03/2025 02:38 PM]
06/03/2025	52	CURED DEFECTIVE DOCUMENT, Motion, at entry 50, on behalf of Appellant Marcus Brent Fields, FILED. [Entered: 06/03/2025 02:40 PM]

Date Filed	Entry #	Public Docket Text
06/03/2025	53	PAPERS, motion for monetary reduction and error in USDC-SDNY, RECEIVED. [Entered: 06/03/2025 02:48 PM]
06/05/2025	54	MOTION ORDER, granting motion for permission to attach exhibits at docket entry 51, on behalf of Appellant Marcus Brent Fields, by ECL, copy to pro se Appellant and Appellee, FILED. [Entered: 06/05/2025 01:02 PM]
06/16/2025	55	UNDELIVERABLE MAIL, for Appellee Albert Bourla to USCA from USPS, received on 06/16/2025, RECEIVED. [Entered: 06/17/2025 01:04 PM]
06/24/2025	56	MOTION, to add exhibits and for default judgment, on behalf of Appellant Marcus Brent Fields, FILED. Service date 06/12/2025 by United States Mail. [Entered: 06/25/2025 12:33 PM]

Docket as of 6/25/2025 3:54 PM

24-2735

REC.
7-14-2025

Marcus Brent Fields, V46240
Richard J. Donovan Correctional Facility
480 Alta Road
San Diego, CA 92179

**UNITED STATES COURT OF APPEALS
FOR THE
SECOND CIRCUIT**

At a Stated Term of the United States Court of Appeals for the Second Circuit, held at the Thurgood Marshall United States Courthouse, 40 Foley Square, in the City of New York, on the 1st day of July, two thousand twenty-five.

Before: Eunice C. Lee,
Circuit Judge.

Marcus Brent Fields,

Plaintiff - Appellant,

v.

Pfizer Inc., Albert Bourla, CEO, Drew Weissman,
Covid-19 MRNA Inventor, Katalin Kariko, Bio-N-Tech,
Bio-Chemist, John and Jane Does, Scientist-Chemist-
Physicist, Ugar Sahin, Bio-N-Tech C.E.O.,

Defendants - Appellees.

ORDER



Docket No. 24-2735

Appellant, pro se, moves to submit additional exhibits to his pending motion for reconsideration en banc and for default judgment.

IT IS HEREBY ORDERED that the motion to submit exhibits is DENIED. The motion for default judgment is DENIED as moot in light of this Court's April 17, 2025 order dismissing the appeal.

For the Court:

Catherine O'Hagan Wolfe,
Clerk of Court

Marcus Brent Fields, V46240
Richard J. Donovan Correctional Facility
480 Alta Road
San Diego, CA 92179

NY

§-18-2025

REC

See
28 USC 1915(g) my first
filing in 2028
& my sep. 2024
which 28 USC 1915g
would have - ~~st~~ still
should be appeal

sent
4-23-25

UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT

Thurgood Marshall U.S. Courthouse 40 Foley Square, New York, NY 10007 Telephone: 212-857-8500

MOTION INFORMATION STATEMENT

Docket Number(s): 24-2735

Caption [use short title]

Motion for: Rehearing - EN - Banc
Review -

Marcus Brent Fields
Plaintiff

Set forth below precise, complete statement of relief sought:

I'm requesting - EN - Banc Review
Due to the fact - I sent all my heart
test - medical - EKG's - Genetics
the best I could Pro-SE

✓

Pfizer et al

MOVING PARTY: Pro-SE Plaintiff - Mr. Fields OPPOSING PARTY: Pfizer et al

☒ Plaintiff

☐ Defendant

☐ Appellant/Petitioner

☐ Appellee/Respondent

MOVING ATTORNEY: Pro-SE Plaintiff OPPOSING ATTORNEY: Pfizer et al

[name of attorney, with firm, address, phone number and e-mail]

Marcus Brent Fields #V-416240 Pfizer Inc [Pro SE]

RJD - 480 Alta Road 66 Hudson Boulevard East

San Diego, CA, 92174 New York, N.Y. 10017

Court- Judge/ Agency appealed from: S.D.N.Y. - NYC - 24-CV-6653 - Swain C.J.

Please check appropriate boxes:

Has movant notified opposing counsel (required by Local Rule 27.1):

☒ Yes ☐ No (explain): _____

FOR EMERGENCY MOTIONS, MOTIONS FOR STAYS AND
INJUNCTIONS PENDING APPEAL:

Has this request for relief been made below? ☐ Yes ☐ No

Has this relief been previously sought in this court? ☐ Yes ☐ No

Requested return date and explanation of emergency: _____

Opposing counsel's position on motion:

☐ Unopposed ☐ Opposed ☒ Don't Know

Does opposing counsel intend to file a response:

☐ Yes ☐ No ☒ Don't Know

Is the oral argument on motion requested?

☐ Yes ☒ No (requests for oral argument will not necessarily be granted)

Has the appeal argument date been set?

☐ Yes ☒ No If yes, enter date: _____

Signature of Moving Attorney:

[Signature]

Date: April 24, 2025 Service: ☐ Electronic ☒ Other [Attach proof of service]

Sent
4-23-25

UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT

Thurgood Marshall U.S. Courthouse 40 Foley Square, New York, NY 10007 Telephone: 212-857-8500

MOTION INFORMATION STATEMENT

Docket Number(s): 24-2735 Caption [use short title] _____

Motion for: Decrease in monetary damages Marcus Brent Fields
to \$30 million Dollars Each Defendant Plaintiff
If Pfizer - fixes my heart / pain reduction

Set forth below precise, complete statement of relief sought:

\$30 Million monetary damages equals.
Reduction - I just want my heart
and Body Pains to stop or decrease
- I give the courts or Pfizer permission
under the courts supervision for all
and any medical test - California COCR
has been - zero help and evasive

MOVING PARTY: Marcus Brent Fields Pro SE OPPOSING PARTY: Pfizer et al

☒ Plaintiff

☐ Defendant

☐ Appellant/Petitioner

☐ Appellee/Respondent

MOVING ATTORNEY: Marcus B Fields OPPOSING ATTORNEY: Pfizer et al

[name of attorney, with firm, address, phone number and e-mail]

Marcus Brent Fields # V-46240 Pfizer Inc [Pro SE]

RJD 480 Alta Road 66 Hudson Boulevard Blvd

San Diego - CA - 92179 New York - NY - 10017

Court- Judge/ Agency appealed from: S.D.N.Y - NYC - 24-CV-6653 - Swain C.J

Please check appropriate boxes:

Has movant notified opposing counsel (required by Local Rule 27.1):

☒ Yes ☐ No (explain): _____

FOR EMERGENCY MOTIONS, MOTIONS FOR STAYS AND
INJUNCTIONS PENDING APPEAL:

Has this request for relief been made below?

☐ Yes ☒ No

Has this relief been previously sought in this court?

☐ Yes ☒ No

Requested return date and explanation of emergency: _____

Opposing counsel's position on motion:

☐ Unopposed ☐ Opposed ☒ Don't Know

Does opposing counsel intend to file a response:

☐ Yes ☐ No ☒ Don't Know

Is the oral argument on motion requested?

☐ Yes ☒ No (requests for oral argument will not necessarily be granted)

Has the appeal argument date been set?

☐ Yes ☒ No If yes, enter date: _____

Signature of Moving Attorney:

[Signature] Date: 4-23-2025 Service: ☐ Electronic ☒ Other [Attach proof of service]

**UNITED STATES COURT OF APPEALS
FOR THE
SECOND CIRCUIT**

At a Stated Term of the United States Court of Appeals for the Second Circuit; held at the Thurgood Marshall United States Courthouse, 40 Foley Square, in the City of New York, on the 5th day of June, two thousand twenty-five.

Before: Eunice C. Lee,
Circuit Judge.

Marcus Brent Fields,

Plaintiff - Appellant,

v.

Pfizer Inc., Albert Bourla, CEO, Drew Weissman, Covid-19
MRNA Inventor, Katalin Kariko, Bio-N-Tech, Bio-
Chemist, John and Jane Does, Scientist-Chemist-
Physicist, Ugar Sahin, Bio-N-Tech C.E.O.,


Defendants - Appellees.

Appellant, pro se, moves for leave to attach exhibits to his motion for reconsideration en banc.

IT IS HEREBY ORDERED that the motion is GRANTED.

For the Court:

Catherine O'Hagan Wolfe,
Clerk of Court


The signature is written in cursive over a circular court seal. The seal contains the text "UNITED STATES", "SECOND CIRCUIT", and "COURT OF APPEALS".

24-2735

Marcus Brent Fields, V46240
Richard J. Donovan Correctional Facility
480 Alta Road
San Diego, CA 92179

REC - 7-15-2025